Study  #[ADDRESS_794246]  Leos  Cleaning  and Disinfecti ng Solution  
PROTOCOL  
STUDY#932  
Sponsor.  
Bausch  + Lomb,  lncorporated 
This clinical  investigation  is being conducted  in accordance  with 21CFR  Paru SO, S4, Sfi and  812, 42 USC 
212(j).  The pro tocol was developed with conside ration of the provision in: ISO 1415S -1:2011 Clinical 
investigation of medical devices for human subjects  - Part I: Official  requiremen ts 14ISS -2:2011 Part 2: 
Clinical investigation of medical devices for human subjects  - Part 2: Clinical investigationa l plan; ISO 
[ZIP_CODE]:2012 Ophthalmic Oplit:[ADDRESS_794247] lens care products  • Guidance for clinical 
investi gations;  ICH GCPs;  and applicable  local  regulations.  
Revision  Chronology:  
Original 
Amendment  I 06FEB2019 
l3FEB2019  
Date: 13FEB2019  Page  1 of 65  [STUDY_ID_REMOVED]
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794248]  Lens  Cleaning  and Disinfecting  Solution  
 
 
PROTOCOL 
STUDY  #[ADDRESS_794249] this  study  in accordance  with 21CFR Parts  50, 54, 56 and 812, 42 USC 
282(j),  and with consideration  of the provision  in: ISO [ZIP_CODE] -1:2011  Clinical  investigation 
of medical  devices  for human  subjects  – Part 1: General requirements;  [ZIP_CODE] -2:2011  Part 
2: Clinical investigation of medical devices for human subjects – Part 2 : Clinical 
investigational  plan;  ISO [ZIP_CODE]:2012  Ophthalmic  Optics  – Contact  [CONTACT_599825] – Guidance for clinical investigations; ICH GCPs; and applicable local 
regulations. I will not initiate the study until I have obtained written approval by [CONTACT_599826]. I will obtain written 
informed consent (and, if applicable, assent for children) from each study subject prior to 
performing any study specific procedures.  
I understand that my sign ature on this document indicates my agreement to this clinical 
Investigational Plan/Protocol and to review and, if appropriate, sign the clinical study 
report.  
I understand  that my signature  [CONTACT_599869] [INVESTIGATOR_048].  
I understand that this document and related information is subject to confidentiality  terms 
found in my  signed Confidentiality  or Clinical Services Agreement. I  agree to protect the 
confidentiality of my patients when a llowing the Sponsor of this clinical investigation, 
and/or relevant regulatory authorities and IRBs, direct access to my medical records for 
study subjects.  
 
 
 
 
Principal  Investigator,  Printed  Name  
 
 
 
 
[CONTACT_270511],  Signature  [CONTACT_599870]  #932  - Protocol  
Date:  13FEB2019  Page  3 of 65  
  
PERSONNEL  AND  FACILTIES  
NOTE:  The information on this page is subject to change. All changes will be provided under separate 
cover.  
 
Sponsor  
Bausch  + Lomb,  Inc. 
[ADDRESS_794250]  
[COMPANY_002]ster,  NY [ZIP_CODE]  
US 

Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794251]  OF ABBREVIATIONS  ................................ ................................ ................................ .........................  7 
1.0  INTRODUCTION  ................................ ................................ ................................ ................................ . 8 
2.0  OBJECTIVE  ................................ ................................ ................................ ................................ ..........  8 
3.0 STUDY  DESIGN  ................................ ................................ ................................ ................................ ... 8 
3.1 DESCRIPTION  OF STUDY  DESIGN  ................................ ................................ ................................ ................................ .. 8 
3.2 SELECTION  OF STUDY  POPULATION  ................................ ................................ ................................ ............................  9 
3.2.1 ELIGIBILITY  ................................ ................................ ................................ ................................ ................................ .......10 
[IP_ADDRESS]  INCLUSION  CRITERIA  ................................ ................................ ................................ ................................ ........10 
[IP_ADDRESS]  EXCLUSION  CRITERIA  ................................ ................................ ................................ ................................ ....... [ADDRESS_794252] ARTICLE -(TEST) ................................ ................................ ............................  [ADDRESS_794253]  (CONTROL ) ................................ ................................ ...... [ADDRESS_794254]  INSTRUCTIONS  ................................ ................................ ................................ ................................ ................  15 
4.4 PACKAGING  AND  LABELING  ................................ ................................ ................................ ................................ ........15 
4.4.1 LENSES  ................................ ................................ ................................ ................................ ................................ ............... 15 
4.4.2 STUDY  KITS ................................ ................................ ................................ ................................ ................................ ......15 
4.4.3 OTHER  STUDY  SUPPLIES  ................................ ................................ ................................ ................................ ............... 16 
4.5 ACCOUNTABILITY  ................................ ................................ ................................ ................................ ........................... 16 
4.6 MASKING /UNMASKING  ................................ ................................ ................................ ................................ ................. [ADDRESS_794255]  REPLACEMENT  ................................ ................................ ................................ ................................ ............. 17 
5.0 SAFETY  AND  EFFECTIVENESS  VARIABLES  ................................ ................................ ............  18 
5.1 SAFETY  VARIABLES  ................................ ................................ ................................ ................................ ....................... 18 
5.2 PRIMARY  EFFECTIVENESS  VARIABLES  ................................ ................................ ................................ ..................... 18 
5.3 RISK ASSESSMENT  ................................ ................................ ................................ ................................ .......................... 18 
6.0 STUDY  METHODS  ................................ ................................ ................................ .............................  18 
6.1 STUDY  VISITS  ................................ ................................ ................................ ................................ ................................ ...18 
6.1.1 SCREENING /DISPENSING  VISIT ................................ ................................ ................................ ................................ ....[ADDRESS_794256]-STUDY  FOLLOW -UP ................................ ................................ ................................ ................................ .............  28 
6.3 STUDY  COMPLETION  ................................ ................................ ................................ ................................ ......................  29 
6.3.1 STUDY  COMPLETION  ................................ ................................ ................................ ................................ ......................  29 
6.3.2 EARLY  STUDY  TERMINATION /SUSPENSION  ................................ ................................ ................................ ............ 29 
Study  #932  - Protocol  
Date:  13FEB2019  Page  5 of 65  
 6.4 CONCOMITANT  MEDICATIONS /THERAPY  ................................ ................................ ................................ ................ 29 
6.5 TREATMENT  COMPLIANCE  ................................ ................................ ................................ ................................ ............ 29 
6.6 PROTOCOL  DEVIATIONS  ................................ ................................ ................................ ................................ ................ 29 
7.0 ADVERSE  EVENTS  ................................ ................................ ................................ ...........................  30 
7.1 ADVERSE  EVENT  DEFINITIONS  ................................ ................................ ................................ ................................ ... 30 
7.1.1 ADVERSE  EVENT  (AE)  ................................ ................................ ................................ ......................  [ADDRESS_794257]  (ADE)  ................................ ................................ ................................ ..... 30 
[IP_ADDRESS]  ANTICIPATED  SERIOUS  ADVERSE  DEVICE  EFFECT  (ASADE)  ................................ .................  30 
[IP_ADDRESS]  UNANTICIPATED  SERIOUS  ADVERSE  DEVICE  EFFECT  ([LOCATION_003]DE)  ................................ .............  31 
7.1.3 SERIOUS  ADVERSE  EVENT  (SAE)  ................................ ................................ ................................ ...... 31 
7.1.4 SIGNIFICANT  NON-SERIOUS  ADVERSE  EVENTS  ................................ ................................ ................................ ....32 
7.1.5 NON-SIGNIFICANT  NON-SERIOUS  ADVERSE  EVENTS  ................................ ................................ .......................... 32 
7.2 ADVERSE  EVENT  TREATMENT  AND  CULTURING  ................................ ................................ ................................ ..33 
7.3 EVALUATIONS  ................................ ................................ ................................ ................................ ................................ ..33 
7.3.1 SEVERITY  ................................ ................................ ................................ ................................ ................................ ...........  33 
7.3.2 RELATIONSHIP  TO STUDY  DEVICE  AND/OR REWETTING  DROPS  ................................ ................................ ......[ADDRESS_794258]  REPORTING ................................ ............... 35 
7.4.2 REPORTING  DEVICE  DEFICIENCIES  ................................ ................................ ................................ ............................. 35 
7.4.3 GUIDELINES  FOR  REPORTING  PREGNANCIES ................................ ................................ ................................ ............ 35 
8.0 STATISTICAL  METHODS  ................................ ................................ ................................ ...............  37 
8.1 STUDY  ENDPOINTS  ................................ ................................ ................................ ................................ .........................  37 
8.1.1 PRIMARY  EFFECTIVENESS  ENDPOINTS  ................................ ................................ ................................ ..................... 37 
8.1.2 SECONDARY  EFFECTIVENESS  ENDPOINTS  ................................ ................................ ................................ ............... 37 
8.1.3 PRIMARY  SAFETY  ENDPOINT  ................................ ................................ ................................ ................................ .......37 
8.2 HYPOTHESES ................................ ................................ ................................ ................................ ................................ .....37 
8.2.1 OVERALL  COMFORT  AVERAGED  OVER  ALL FOLLOW -UP VISITS  ................................ ................................ ....37 
8.2.2 DRYNESS  AVERAGED  OVER  ALL FOLLOW -UP VISITS  ................................ ................................ ......................... 37 
8.2.3 LENS  DEPOSITS  AT ALL FOLLOW -UP VISITS  ................................ ................................ ................................ .......... 37 
8.2.4 SLIT LAMP  FINDINGS  GREATER  THAN  GRADE  2 ................................ ................................ ................  38 
8.3 SAMPLE  SIZE ................................ ................................ ................................ ................................ ................................ .....38 
8.3.1 OVERALL  COMFORT  ................................ ................................ ................................ ................................ ....................... 38 
8.3.2 DRYNESS  ................................ ................................ ................................ ................................ ................................ ............ 38 
8.3.3 LENS  DEPOSITS  ................................ ................................ ................................ ................................ ................................ 38 
8.3.4 SLIT LAMP  FINDINGS  GREATER  THAN  GRADE  2 ................................ ................................ ................  38 
8.3.5 OVERALL  POWER  ................................ ................................ ................................ ................................ ............................ 39 
8.3.6 ENROLLMENT  TARGET  ................................ ................................ ................................ ................................ .................. 39 
8.4 RANDOMIZATION  ................................ ................................ ................................ ................................ ............................ 39 
8.5 STUDY  POPULATIONS  ................................ ................................ ................................ ................................ ..................... 39 
8.5.1 INTENT -TO-TREAT  (ITT)  POPULATION ................................ ................................ ................................ ..................... 39 
8.5.2 PER PROTOCOL  (PP) POPULATION  ................................ ................................ ................................ .............................. 39 
8.5.3 SAFETY  POPULATION  ................................ ................................ ................................ ................................ .....................  39 
8.6 STATISTICAL  ANALYSIS  ................................ ................................ ................................ ................................ ................ 40 
8.6.1 METHODS  OF ANALYSIS  ................................ ................................ ................................ ................................ ...............  40 
[IP_ADDRESS]  GENERAL  METHODS  ................................ ................................ ................................ ................................ ..........  40 
[IP_ADDRESS]  OVERALL  COMFORT  ................................ ................................ ................................ ................................ .......... 40 
[IP_ADDRESS]  DRYNESS  ................................ ................................ ................................ ................................ ............................... 40 
[IP_ADDRESS]  LENS  DEPOSITS  ................................ ................................ ................................ ................................ ................... 40 
[IP_ADDRESS]  GRADED  SLIT LAMP  FINDINGS  > GRADE  [ADDRESS_794259]  DISCONTINUATION  ................................ ................................ ................................ ................................ ........41 
8.6.4 PROTOCOL  DEVIATIONS  ................................ ................................ ................................ ................................ ................ 41 
8.6.5 TREATMENT  COMPLIANCE  ................................ ................................ ................................ ................................ ............ 42 
8.6.6 TREATMENT  EXPOSURE  ................................ ................................ ................................ ................................ ................ 42 
8.6.7 MISSING  DATA  ................................ ................................ ................................ ................................ ................................ .42 
8.6.8 INTERIM  ANALYSES ................................ ................................ ................................ ................................ ........................ 42 
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794260]  ................................ ................................ ................................ ................................ 44 
9.7 PUBLICATION  OF RESULTS  ................................ ................................ ................................ ................................ ........... 45 
10.0 REFERENCES  ................................ ................................ ................................ ................................ .... 46 
 
 
APPENDICES  
APPENDIX  A: SCHEDULE  OF VISITS  AND  PARAMETERS..................................................  A-1 
APPENDIX B:  METHODS  OF CLINICAL  EVALUATION  ........................................................B -1 
APPENDIX  C: SUBJECT  INSTRUCTIONS  .................................................................................  C-1 
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794261]  OF ABBREVIATIONS  
 
Abbreviation  
/Acronym  Term  
AADE  Anticipated  Adverse  Device  Effect  
ADE  Adverse  Device  Effect  
AE Adverse  Event  
ASADE  Anticipated  Serious  Adverse  Device  Effect  
BSCVA  Best Spectacle  Corrected  Visual  Acuity  
CFR Code  of Federal  Regulations  
CRA  Clinical  Research  Associate  
D Diopter  
DOB  Date  of Birth  
eCRF  Electronic  Case  Report  Form  
FDA  United  States  Food  and Drug  Administration  
GCPs  Good  Clinical  Practices  
GP Gas Permeable  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
ICF Informed  Consent  Form  
ICH International  Conference  on Harmonisation  
ID Identification  
IRB Institutional  Review  Board  
ISO International  Standards  Organization  
ITT Intent -to-Treat  
logMAR  Logarithm  of the Minimum  Angle  of Resolution  
MCMC  Markov  chain  Monte  Carlo  
mm Millimeter  
OD Right  Eye 
ORS  Oracle  Randomization  System  
OS Left Eye 
PP Per Protocol  
PMMA  Polymethylmethacrylate  
SAE Serious  Adverse  Event  
Tel Telephone  
[LOCATION_003]DE  Unanticipated  Serious  Adverse  Device  Effect  
US United  States  
VA Visual  Acuity  
NOTE:  The first occurrence  of some  abbreviations  is not spelled  out in the document  (e.g.,  units  of 
measure).  
Study  #932  - Protocol  
Date:  13FEB2019  Page  8 of 65  
  
1.0 INTRODUCTION  
Bausch + Lomb is evaluating an investigational cleaning and disinfecting solution, BL - 
ABT12 Multi -Purpose Solution (“ABT12 Multi -Purpose Solution”), for use with soft 
contact [CONTACT_13276].  The aim of this study is to evaluate the safety and effectiveness of the  
investigational ABT12 Multi -Purpose Solution when compared to a currently marketed 
COMPLETE® Multi -Purpose  Solution  Easy  Rub® Formula  (“COMPLETE  Multi -Purpose 
Solution”).  
ABT12 Multi -Purpose Solution is a sterile isotonic aqueous solution [containing 
polyaminopropyl biguanide (0.[ZIP_CODE]%), polyquaternium -1 (0.[ZIP_CODE]%), and alexidine 
dihydrochloride (0.[ZIP_CODE]%)] for disinfecting, cleaning, conditioning, rinsing, protein 
removal, and storing soft (hydrophilic) and silicone hydrogel contact [CONTACT_13276].  
 
2.0 OBJECTIVE  
The objective of this study is to evaluate the safety and effectiveness of ABT12 Multi - 
Purpose solution (Test) compared to COMPLETE® Multi -Purpose Solution Easy Rub® 
Formula (“COMPLETE Multi -Purpose Solution”) when used by [CONTACT_599827] t o bilaterally clean and disinfect their contact [CONTACT_599828].  
 
3.0 STUDY  DESIGN  
This is a multicenter,  randomized,  masked,  parallel,  bilateral  clinical  trial. 
 
3.1 Description  of Study  Design  
The study is designed to examine whether ABT12 Multi -Purpose Solution cleaning and 
disinfecting solution is non -inferior to COMPLETE Multi -Purpose Solution in several 
primary endpoints.  
Approximately 252 subjects (504 eyes) will be enrolled in this three -month multicenter, 
randomized,  masked,  parallel,  bilateral  study  at approximately  18 investigative  sites in the 
[LOCATION_002] (US). Approximately  one-half of  the subjects will be  randomized to receive 
Bausch  + Lomb  investigational  ABT12  Multi -Purpose  Soluti on (Test),  and approximately 
one-half of the subjects will be randomized to receive COMPLETE® Multi -Purpose 
Solution (Control). In addition, all subjects will be dispensed three new pairs (including 
two back -up pairs)  of their habitual  lenses  at the beginn ing of the study  for daily  wear,  and 
scheduled replacement lenses at the 1 -Month and 2 -Month Follow -up Visits.  
All subjects will be seen for a Screening/Dispensing  Visit, at which the informed consent 
form (ICF), including the Health Insurance Portability  Accountability Act (HIPAA), will 
be obtained  and eligibility  will be assessed.  If eligible,  subjects  will be dispensed  three  new 
pairs  of their habitual  lenses  and a Study  Kit containing  a cleaning  and disinfecting  solution 
(sufficient for the entire study) according to the subject’s unique randomization schedule. 
Subjects may also be dispensed a supply of Sensitive Eyes® Rewetting Drops to be used 
on an as needed ba sis. Subjects must NOT use ANY other cleaning and disinfecting 
solution or rewetting drops during the study.  
Subjects are to wear their study lenses on a daily wear basis, and are to use the Test or 
Control  cleaning  and disinfecting  solution  and care regimen  after removing  the lenses  each 
day. Subjects  will return  their worn  lenses  to the unmasked  designee  at each monthly  
Study  #932  - Protocol  
Date:  13FEB2019  Page  9 of 65  
 follow -up visit, and will return their used and unused study solutions to the unmasked 
designee  at the three  month  follow-up visit (or early  study  termination/suspension  visit)  for 
return to the Sponsor.  
Eligible  subjects  will be enrolled  into one of five lens groups  based  on their habitual  contact 
[CONTACT_13276].  Subjects  will be randomized  on a 1:[ADDRESS_794262] or  Control cleaning  and disinfecting  solution.  The five  lens groups will be 
comprised  of habitual  wearers  of soft lenses  based  on lens material  as indicated  in the table 
below.  
Table  1: Lens  Groups  
 
Lens  Group  Lens  Material  Trade  Name  [CONTACT_83138]  
4 Etafilcon  A Acuvue2  Vistakon  
5-A Balafilcon  A PureVision2  Bausch  + Lomb  
5-C Samfilcon  A Ultra  Bausch  + Lomb  
5-Cm Lotrafilcon  B Optix  Aqua  Alcon  
5-Cr Senofilcon  C Vita Vistakon  
 
3.[ADDRESS_794263] (IRB) and Sponsor approval to conduct the study. The Sponsor and  IRB 
must approve any advertising used to recruit subjects prior to use of that advertising.  
All consented  subjects  must  be accounted  for, whether  they participate  in the study  or not. 
Bausch + Lomb will provide a Screening and Enrollment Log on which to e nter 
information for each subject who signs an ICF. Once a potential subject is consented and 
their initials are entered onto the Screening and Enrollment Log, the Investigator should 
proceed with screening procedures.  
Potential  subjects  are deemed  either  “Screen  Pass”  or “Screen  Fail.”  “Screen  Fail”  subjects 
have not met the study inclusion criteria or have met the exclusion criteria. “Screen Fail” 
subjects  cannot participate  in the study.  Electronic case  report forms  (eCRFs)  must not be 
completed for “Scr een Fail” subjects; however, the copy of their signed ICF and any 
information collected as part of screening (e.g., source documents, etc.) must be kept in 
their medical records.  
“Screen  Pass”  subjects  have  met all of the study  inclusion  criteria  and have  not met any of 
the exclusion criteria. Only “Screen Pass” subjects are eligible to participate in the study 
and will be assigned a subject identification (ID) number from the randomization system.  
Once  a subject  is randomized  (i.e., a subject  ID numbe r is assigned),  a subject  is considered 
active and must be accounted for at every visit until exited (completed or discontinued) 
from the study, even if they are not dispensed study materials. Refer to Section 3.2.[ADDRESS_794264] to fo llow-up. 
Study  #932  - Protocol  
Date:  13FEB2019  Page  10 of 65  
 3.2.1 Eligibility  
 
[IP_ADDRESS]  Inclusion  Criteria  
The subject is eligible for entry into the study if the subject meets all of the 
following criteria:  
1. Is of legal age  (at least 18) on the date the Informed  Consent Form (ICF)  is 
signed and has the capacity to provide voluntary informed consent.  
2. Is able to read, understand, and provide written informed consent on the 
Institutional Review Board (IRB) approved ICF and provide authorization 
as appropriate for local privacy regulati ons. 
3. Is a habitual  wearer  (at least 3 months)  of one of the following  lens types:  
 
Lens  Group  Lens  Material  Trade  Name  [CONTACT_83138]  
4 Etafilcon  A Acuvue2  Vistakon  
5-A Balafilcon  A PureVision2  Bausch  + Lomb  
5-C Samfilcon  A Ultra  Bausch  + Lomb  
5-Cm Lotrafilcon  B Optix  Aqua  Alcon  
5-Cr Senofilcon  C Vita Vistakon  
4. Is correctable  through  spherocylindrical  refraction  to 32 letters  
(0.3 logMAR) or better (distance, high contrast) in each eye with soft 
spherical contact [CONTACT_13276].  
5. Has clear  central  corneas  and is free of any anterior  segment  disorders.  
6. Is a habitual  user of a lens care product  for cleaning,  disinfecting,  and 
storage of lenses . 
7. Requires  lens correction  in both eyes.  
8. Wears  the same  manufacturer  and brand  of lens in both eyes.  
9. Agrees to wear study lenses on a daily wear basis for approximately three 
months.  
10. Is willing  and able to comply  with all treatment  and follow -up/study  
procedures.  
 
[IP_ADDRESS]  Exclusion  Criteria  
The subject is ineligible for entry  into the study  if the subject meets any of the 
following criteria:  
1. Subjects who currently use a hydrogen -peroxide cleaning and disinfecting 
solution  
2. Participating  in any drug  or device  clinical  investigation  within  30 days 
prior  to entry  into this study  and/or  during  the period  of study  participation.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  11 of 65  
 3. Females  of childbearing  potential  (those  who are not surgically  sterilized  or 
postmenopausal) if they meet any one of the following conditions:  
− they are currently  pregnant  
− they plan to become  pregnant  during  the study  
− they are breastfeeding  
4. Has worn  gas permeable  (GP)  lenses  within  the last 30 days.  
5. Has worn  polymethylmethacrylate  (PMMA)  lenses  within  the last 
three months.  
6. Has any systemic disease currently affecting ocular health or which in the 
Investigator’s  opi[INVESTIGATOR_599816].  
7. Has any ocular  disease  or is using  any ocular  medication.  
8. Is using any  systemic or topi[INVESTIGATOR_240341], in the Investigator’s 
opi[INVESTIGATOR_1649], affect ocular physiology or lens performance.  
9. Currently  wears  monovision,  multifocal,  or toric contact  [CONTACT_13276].  
10. Has ocular  astigmatism  of 1.00D  or greater  in either  eye. 
11. Is not correc table  through  spherocylindrical  refraction  to 32 letters 
(0.3 logMAR) or better (distance, high contrast) in each eye with soft 
spherical contact [CONTACT_13276].  
12. Has anisometropia  (spherical  equivalent)  of greater  than 2.00D.  
13. Has any grade 2 or greater finding during the slit lamp examination (refer 
to Appendix B for Methods of Clinical Evaluation).  
14. Has corneal  infiltrates,  of ANY  GRADE.  
15. Subjects  with any “Present”  finding  during  the slit lamp  examination  (refer 
to Appendix  B for methods  of clinical  evaluation)  that, in the Investigator’s 
judgment, interferes with contact [CONTACT_13279].  
16. Has any scar or neovascularization within the central 6 mm of the cornea. 
Note that subjects with minor peripheral corneal scarring (that does not 
extend into the central area), that, in the Investigator’s judgment, does not 
interfere with contact [CONTACT_13279], are eligible for this study.  
17. Is aphakic.  
18. Is amblyopic.  
19. Has had any corneal  surgery  (e.g.,  refractive  surgery).  
20. Is allergic  to any component  in the study  care products.  
21. Is an employee  of any of the study  investigative  sites or a family  member  of 
an employee of the investigative site, including family members living 
outside of the employee’s household.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794265], an Optician, or an Ophthalmic 
Assistant/Technician, or currently resides with a person with any of these 
specialties.  
23. Is an employee of a manufacturer of contact [CONTACT_599829] (e.g., Alcon, Baus ch + Lomb, Ciba Vision, CooperVision, 
Vistakon, [COMPANY_012], etc.) or currently resides with a person 
employed by [CONTACT_599830].  
If a subject meets  all the  inclusion  criteria  and does not meet any  of the exclusion  criteria, 
the subject i s eligible for entry  into the study. Ineligible subjects MUST NOT be enrolled 
in this study. Any subject enrolled in the study who later is found to have not met the 
eligibility criteria at entry will be discontinued.  
 
3.2.[ADDRESS_794266] has co mpleted the study when the Exit Visit is concluded at the 3 -Month 
Follow -up Visit.  Subjects  who require  further  follow -up for an adverse  event  (AE)  will be 
followed according to Section 6.2.  
 
3.2.[ADDRESS_794267] MAY be discontinued (at the di scretion of the Investigator, the Sponsor, and/or 
the IRB)  prior  to the final study  visit for a variety  of reasons,  including,  but not limited  to: 
• An adverse  event (AE)  occurring  during  the course  of the study,  which  precludes 
continued treatment or follow -up 
• Persistent  grade  3 or 4 slit lamp  findings  (must  be reported  to the Sponsor  within 
24 hours)  
• Persistent  study  related  symptoms/complaints  
• Unacceptable  distance  lens visual  acuity  (VA)  
• Unacceptable  lens centration  
• Unacceptable  lens movement  
• Other  reasons  related  to failure  to follow  study  procedures  
A subject  MUST  be discontinued  prior  to the final study visit  for any of  the following 
reasons:  
• Voluntary  withdrawal  
• Death  
• Investigator  decision  that it is not in the best medical  interest  of the subject  to 
continue participation in the investigation  
• Ineligible  at baseline  - does not meet  the eligibility  criteria  in the protocol  
• Inability  to maintain  recommended  wearing  schedule  
• Lack  of motivation  
• Continued  failure  to follow  subject  instructions  
• Misses  any follow -up visit 
• Lost to follow -up (refer  to Section  3.2.4)  
• Instillation  of non-medically  indicated  solution  not specified  in the protocol  
• Either  eye is discontinued  
• Becomes  pregnant  during  the study  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794268] discontinuations will be documented clearly on the source document and 
applicable eCRF. The Investigator should indicate the PRIMARY (one) reason that the 
subject was discontinued for each eye. Subjects that are discontinued fr om the study 
following randomization will not be replaced.  
Exit Visit  assessments  should  be completed  for early  discontinued  subjects,  if possible.  
 
3.2.[ADDRESS_794269]’s source documentation, and the 
applicable eCRFs will be completed.  Just prior to database lock, the database will be 
reviewed for all lost to follow -up entries to confirm, once again, that contact [CONTACT_599831].  
 
3.3 Investigators  
The study will be conducted at approximately 1 8 investigative sites located in the US by 
[CONTACT_367793] + Lomb to be suitably qualified by [CONTACT_367794]. Principal Investigators will sign the Device 
Investigator Agreement form prior to the st art of the study.  
Each  Investigator  will enroll  approximately  14 subjects,  28 eyes.  In the event  that selected 
sites do not meet  full enrollment,  the Sponsor  may decide  to increase  enrollment  as needed 
at other currently active sites and/or additional site(s) may be added to satisfy the 
enrollment requirements of the study.  
 
3.[ADDRESS_794270]  four (4) weeks  from  the enrollment  start date communicated  by [CONTACT_599832]/Dispensing Visits.  
Subjects will be followed for approximately  three (3) months (unless discontinued or lost 
to follow -up) from  the initial  Screening/Dispensing  Visit  and must  adhere  to the following 
schedule:  
 
SCHEDULED  FOLLOW -UP VISITS  
Visit  Target  Acceptable  Visit  Range  
(from  Screening/Dispensing  Visit)  
2-Week  Follow -up Visit 14 Days  10 - 18 Days  
1-Month  Follow -up Visit 30 Days  26 – 34 Days  
2- Month  Follow -up Visit 60 Days  53 – 67 Days  
3-Month  Follow -up Visit 90 Days  83 – [ADDRESS_794271] articles are initially dispensed 
(Screening/Dispensing  Visit).  A visit scheduling  table  will be  provided  in the initial study 
shipment to aid the Investigator in scheduling follow -up visits.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  14 of 65  
 3.5 Treatments  
Eligible subjects will be randomized to use ABT12 Multi -Purpose Solution (Test) or 
COMPLETE  Multi -Purpose  Solution  (Control).  At the initial  Screening/D ispensing  Visit, 
each subject will be provided with a Study Kit (containing Test or Control solution 
sufficient for the full study  duration, study  lens cases, and Subject Instructions), and with 
other study  supplies as needed (e.g., Sensitive Eyes® Rewetti ng Drops and product return 
materials).  Subjects will be  required to wear  dispensed study  lenses on a  daily  wear  basis 
for three months with scheduled in -office replacement of study  lenses at the 1 -Month and 
2-Month Follow -Up Visits.  
 
4.0 STUDY  MATERIALS  
Bausc h + Lomb will provide all study  solutions and Bausch + Lomb lenses at no charge 
to the Investigator.  All other  study  lenses  (non B+L brands)  are to be purchased  through 
the site’s normal ordering process and will be reimbursed by [CONTACT_1034].  All other 
materials will be provided to the site prior to the start of the study.  Refer to Product 
Replacement Section 4.[ADDRESS_794272] Article -(Test)  
ABT12 Multi -Purpose Solution cleaning and disinfecting solution is a sterile isotonic 
aqueous solution containing polyaminopropyl biguanide (0.[ZIP_CODE]%), polyquaternium -1 
(0.[ZIP_CODE]%), and alexidine dihydrochloride (0.[ZIP_CODE]%) for disinfecting, cleaning, 
condit ioning,  rinsing,  protein  removal,  and storing  soft (hydrophilic)  and silicone  hydrogel 
contact [CONTACT_13276].  
 
4.[ADDRESS_794273]  (Control)  
COMPLETE® Multi -Purpose  Solution  Easy  Rub® Formula  (“COMPLETE  Multi -Purpose 
Solution”) cleaning and disinfecting solution (Control) is indicated for the care of soft 
contact [CONTACT_13276].  COMPLETE Multi -Purpose Solution is a sterile, isotonic, buffered 
solution, preserved with polyhexamethylene biguanide (0.0001%), a phosp hate buffer, 
Poloxamer  237, edetate  disodium,  sodium  chloride,  potassium  chloride,  and purified  water.  
 
4.[ADDRESS_794274] will be issued a Study Kit labeled with a unique Study 
Kit number.  Subjects  will be dispensed  three  pairs  (two for back -up) of their habitual  lenses 
at the Screening/Dispensing Visit with additional pairs of lenses be ing dispensed at each 
of the monthly follow -up visits.  Subjects will wear their assigned lenses on a daily wear 
basis for the duration of the study.  
The Investigator  or designee  will instruct all subjects  to adhere  to the Subject Instructions 
provided with  their study lens care solution carton for daily care of their contact [CONTACT_13276].  
Study  #932  - Protocol  
Date:  13FEB2019  Page  15 of 65  
 In order  to ensure  that the Investigator  and site staff remain  masked  to the lens care system, 
an unmasked designee at the site will be responsible for all dispensation and collection of 
study supplies to/from the subjects.  
Subjects are to be instructed not to discuss or show the dispensed study products or  
lens care system to the Investigat or or masked site staff during the study.  
 
4.3.[ADDRESS_794275] Instructions for the use of stud y articles (refer to 
Appendix C for Subject Instructions). Subjects must comply with the instructions 
provided to them. Subject Instructions will be included with each carton of study 
solution.  
b. The unmasked  designee  must  review,  with the subject,  the Subje ct Instructions  and the 
precautions  and warnings  for lens wear,  lens care,  handling,  cleaning,  and disinfecting, 
and return of study materials.  
c. Any subject who does not follow instructions to a degree that, in the Sponsor or 
Investigator's  opi[INVESTIGATOR_1649],  jeopardizes  the subject's  well-being  or the validity  of the study, 
will be discontinued.  
 
4.[ADDRESS_794276]’s  habitual  contact  [CONTACT_599833]; three pairs will be dispensed to the subject at the 
Screening/Dispens ing Visit (two for back -up) and a new pair will be dispensed at each of 
the 1-Month  and 2-Month  Follow -up Visits.  The sixth  pair will be retained  in-office  in the 
event that a  non-scheduled  replacement is  required.  Additional lenses  can be ordered  and 
dispensed, if needed.  
 
4.4.[ADDRESS_794277] by [CONTACT_145913].  Each 
Study Kit will include the following materials:  
• 5 bottles  of study  solution  (Test or Control).  Each  labeled  bottle  will be enclosed  in 
a labeled white carton.  Each carton and bottle will be labeled with an investigational 
label including a Study Kit number (a unique 5 -digit number) and a bottle number (1, 
2, 3, 4 or 5). Cartons  containing  bottles  1, 2, 3 and 4 will be provided  to subjects  at the 
Screening/Dispen sing Visit, and the carton containing bottle [ADDRESS_794278] number may be written on the 
outside carton ONLY.  The bottles should not be written on or labelled.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  16 of 65  
 • Lens case.  Will be included with each carton of study solution for the subject to use 
for the month.  Subjects are required to use the supplied lens case.  
• Subject  Instructions.  Will be included  with each carton  of study  solution.  
 
4.4.3 Other  Study  Supplies  
The following  will be stored  at the sites to be provided  to subjects  as needed:  
• Carton/Bottle Return Materials.  Comprised of opaque drawstring bags and pre - 
printed labels for return of Test and Control articles (full, partially full, and empty 
bottles) to the Sponsor.  
• Lens  Return  Materials . Comprised  of sealable  plastic  bags and pre-printed  labels  for 
return of worn lenses to the Sponsor (in a fresh lens case with the approved saline 
solution).  The unmasked designee will place worn lenses in Sensitive Eyes Saline 
Solution  in a supplied  fresh  lens case (not the lens case  that was  used by [CONTACT_599834]). The case will be put in a sealable plastic bag. The preprinted label is 
to be adhered to the sealable plastic bag. Label will identify such information as  
study  number, site identification number, subject number, subject initials, lens type, 
date dispensed,  date removed,  quantity  of lenses  returned  (should  be one lens for each 
eye).  
• Sensitive  Eyes® Rewetting  Drops  
 
Use of other  contact  [CONTACT_599835].  
 
4.[ADDRESS_794279]  be stored  under  the appropriate  conditions  (room  temperature)  in a 
secure area and are to be dispensed only to subjects enrolled in the study,  in accordance 
with the conditions specified in this protocol.  
Upon completion of the study, the field Clinical Research Associates (CRAs) will review 
and verify the Investigator's accountability records.  
Following  verification,  and as directed  by [CONTACT_19457], all used and unused study  supplies 
(study solutions, unused contact [CONTACT_13276], and lens cases including worn lenses) must be 
returned to the Sponsor at the address below:  
Bausch  + Lomb,  Inc. 

Study  #932  - Protocol  
Date:  13FEB2019  Page  17 of 65  
 4.6 Masking/Unmasking  
The Investigator and Sponsor/Sponsor’s representatives involved in the conduct of the 
study will be masked to the study cleaning and disinfecting solutions. The randomization 
schedule will be produced prior to study enrollment and uploaded into ORS.  
The ra ndomization schedule will be created by [CONTACT_599836].  Personnel involved with repackaging of clinical trial material will 
also be unmasked.  Field CRAs will become unmasked during product reconciliation, at 
the conclusion of each site’s participation in the study and prior to locking the database. 
Unmasked  designees  at the site will manage  the dispensation  and return  of study  solutions 
and related supplies. All other study personnel will remain masked until dat abase lock. 
Another research staff member may manage the dispensation of the habitual lenses.  
Study solutions will be provided in sealed opaque white boxes with Study Kit numbers  
preprinted  on them.  Subjects  are not to show  the study  solution  to or discuss  their  care 
regimen with the Investigator or site staff unless instructed to do so.  Subjects may  
discuss any questions they have with the unmasked designee at the site.  
While there will be unique features of each of the solution bottles, efforts wil l be made to 
keep subjects masked to their solution by [CONTACT_599837]’s label.  
In the event that unmasking of a subject’s randomly assigned treatment is required, the 
Investigator (or other designee) is required to contact [CONTACT_171041] l Monitor to request 
permission to unmask.  The Medical Monitor will contact [CONTACT_12064] (Dan 
Donatello,  see Personnel and  Facilities  Page  3) and obtain  approval  to grant  permission  to 
unmask.  Upon receipt of authorization from the Sponsor designee , the Medical Monitor 
will advise the Investigator (or other qualified designee) to log into the randomization 
system and unmask the subject.  If the Medical Monitor cannot be contact[INVESTIGATOR_530], the 
Investigator (or other qualified designee) should then contact [CONTACT_599838] a subject.  In the event  that the Medical  Monitor  or Sponsor 
designee cannot be contact[CONTACT_240367] (or other qualified designee) deems the 
unmasking  emergent,  the Investigator  may log into ORS  without  authorization  and unmask 
the subject.  Whether unmasking occurs inadvertently or intentionally, t he Investigator 
must  notify  the Medical  Monitor  or Sponsor  designee  as soon  as possible  after unmasking. 
In addition,  the Investigator  must  record  the date,  time,  and reason  for unmasking  the study 
treatment in the source documentation.  
 
4.[ADDRESS_794280]  in the event 
that unscheduled  study  kit replenishment  is required.  These  reserve  cartons/bottles  will be 
labeled with an investigational label including a Study Kit number (a unique 5 -digit 
number) and bottle number (bottle 5).  
Any additional/replacement (in the case of loss or damage) Test or Control product must 
be ordered through the randomization system according to the subject randomization.  
A reserve  pair of lenses  for each dispensed  subject  will be retained  in-office  in case a non- 
scheduled  lens replacement  is required  and the subject  already  used their two back -up pairs 
that were dispensed at the Screening/Dispensing Visit.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794281] and Control  solutions  will be determined  by [CONTACT_194468]:  
• The primary  safety  endpoint  will be slit lamp  findings  greater  than grade  2. 
• Adverse Events will also be evaluated. Information regarding any subject - or 
investigator - reported  AEs will be obtained  at each follow -up visit.  The rate of adverse 
events is not a primary endpoint and is not associated with a predefined success 
criterion . 
 
5.[ADDRESS_794282] and Control  solutions  will be determined  by [CONTACT_194468]:  
• Overall  comfort  averaged  over all follow -up visits  
• Dryness  averaged  over all follow -up visits  
• Optimal  (none  or light)  lens deposits  at all follow -up visits  
 
5.[ADDRESS_794283] lens and care 
solution use.  
 
6.0 STUDY  METHODS  
 
6.1 Study  Visits  
Refer to APPENDIX A for a Schedule of Visits and Parameters and APPENDIX B for  
Methods of Clinical Evaluati on. 
Prior to enrollment into the study, the Investigator (or designee) will explain the purpose 
of the study, procedures, risks/benefits, and subject responsibilities to the potential 
participant. The subject’s willingness and ability to meet the follow -up requirements of 
the study will be determined. If the subject chooses to participate in the investigation, 
written ICF, including HIPAA, will be obtained.  The subject and the person obtaining 
written consent will sign and date the IRB -approved ICF.  The Inv estigator should retain 
the signed  original  document  in the subject’s  record  and provide  a copy  to the subject.  In 
addition, the applicable privacy regulation requirements must be met.  
Eligible  subjects  will be required  to complete  and initial  the subject -completed  forms  while 
at the visits listed below. The data will then be transcribed into electronic Case Report 
Forms  (eCRFs)  by [CONTACT_574638].  The original subject -completed forms  will be 
retained by [CONTACT_599839].  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794284] -Completed  Forms  
Screening/Dispensing  Visit Initial  Symptoms/Complaints  (Worn  Lenses  Symptoms/Complaints) 
Symptoms/Complaints (Abbreviated Study Lenses 
Symptoms/Complaints)  
2-Week  Follow -up Visit Symptoms/Complaints  (Study  Lenses  Symptoms/Complaints)  
1-Month  Follow -up Visit Symptoms/Complaints  (Study  Lenses  Symptoms/Complaints)  
2-Month  Follow -up Visit Symptoms/Complaints  (Study  Lenses  Symptoms/Complaints)  
3-Month  Follow -up Visit Symptoms/Complaints  (Study  Lenses  Symptoms/Complaints)  
Unscheduled  Visit(s)  Symptoms/Complaints  (Study  Lenses  Symptoms/Complaints)  
 
 
6.1.1 Screening/Dispensing  Visit 
A Screening and Enrollment Log will be provided by [CONTACT_599840]. Once the Screening and Enrollment Log is complete and all data is 
reviewed and confirmed by [CONTACT_599841], the Investigator will sign and date the form 
verifying  the documented  data is correct.  The Investigator  will retain  a copy  (yellow copy) 
of the original document for their records and the field CRA will submit the original to 
ClinDatrix.  
After obtaining written informed consent, prospective subjects will be screened to 
determine whether they meet the entry criteria for the study.  
The Screening/Dispensing  Visit  will proceed  as follows:  
NOTE:  All VA measurements  MUST  be made  using  a phoropter.  
a. Enter the following information on the next available line of the Screening and 
Enrollment Log:  
− Subject  Number  
− Subject  Initials  
− Subject  Date  of Birth  (DOB)  
− Gender  
− Habitual  Lens  Group  
− Visit  1 (Screening/Dispensing)  Date 
b. Collect  demographic  information  and record  in the subject’s  source  document.  
c. Collect the following baseline lens/lens care history information and lens wear 
parameters from the subject and record in the subject’s source document:  
− Average  daily  wearing  time 
− Hours  lenses  worn  on the day of this visit 
− Average  hours  of comfortable  wear  
− Current  lens brand,  sphere  power  and base curve  
− Current  lens care products  
Study  #932  - Protocol  
Date:  13FEB2019  Page  20 of 65  
 d. Perform the following baseline assessments (without lenses; remove the lenses if the 
subject wore lense s to the visit) and record in the subject’s source document:  
− Spherocylindrical  refraction  
− High  contrast  distance  best spectacle -corrected  visual  acuity  (BSCVA)  
− Keratometry  
e. Perform a slit lamp examination (remove the lenses if the subject wore lenses to the 
visit). Record and sketch any scars and slit lamp findings greater than Grade [ADDRESS_794285]’s source document.  
f. If the subject continues to be eligible, have the subject  complete and initial the 
following form:  
− The Initial Symptoms/Complaints Form (Worn Lenses Symptoms/Complaints 
Form), including use of rewetting drops.  
Site personnel  will transcribe  this information  to the Visit  electronic  Case  Report  Form 
(eCRF), and wi ll retain the original in the study files.  
g. Complete the Initial Lens Performance Assessment Form (Worn Lenses Performance 
Rating Scales).  
h. Dispense three pairs (two for back up only) of the subject’s habitual contact [CONTACT_13276]. 
Explain to the subject that the used lenses will be removed at the follow -up visits and 
returned to the Sponsor.  
i. Instruct  subject  to insert  study  lenses.  
j. Instruct  subject  to complete  Symptoms/Complaints  Form  (Abbreviated  version:  Study 
Lenses Symptoms/Complaints).  
k. Complete  the Lens  Performance  Assessment  Form  (Study  Lenses  Performance  Rating 
Scales).  
l. Record  the following  into the subject’s  source  documentation:  
− Dispensed  lens type (brand),  sphere  power,  base curve  
− High  contrast  distance  lens VA 
− Over -refraction  and distance  VA 
− Lens  wettability  
− Lens  centration  
− Lens  movement  
− For each eye, compare the high contrast distance lens VA to the high contrast 
Distance Best Spectacle -Corrected VA obtained at this visit. If the VA has 
decreased by 5 letters (0.1 logMAR) or more, explain.  
m. Indicate on the Screening and Enrollment Log whet her the subject is a “Screen Pass” 
or “Screen Fail.”  Only “Screen Pass” subjects should be randomized in the study. 
“Screen  Fail”  subjects  are ineligible  and cannot  be randomized  in the study.  No eCRFs 
shall be completed for “Screen Fail” subjects.  
− If the subject is a “Screen Pass” : Log into ORS to randomize the subject.  Enter 
the subject number from ORS on the Screening and Enrollment Log.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  21 of 65  
 − If the subject  is a “Screen  Fail” : the reason  for screen  failure  must  be documented 
on the Screening and Enrollment Log and in the subject record, and maintained 
with a copy of their ICF.  
n. If the subject is a “Screen Pass” the Unmasked Designee should then dispense Study 
Kit bottles  1, 2, 3, and 4 only (keepi[INVESTIGATOR_599817]  5 as a reserve  at the site) (refer  to Section 
4.4.2)  to the subject  and record  in the subject’s  individual  Product  Accountabi lity Log. 
o. The Unmasked  Designee  will explain  to the subject  that: 
− Cartons  and bottles  are NOT  to be opened  in front  of any other  site personnel.  
− The subject  should  retain  all study  materials  during  the course  of the study.  
− Prior to coming to the site for the 3 -month, exit or early study 
termination/suspension visits, follow -up visit or exit visit the subject should: (i) 
place all used and  unused study solution bottles into their original white cartons,  
(ii) place  the cartons  and all lens cases  into the opaque  white  drawstring  return  bag, 
(iii) close  the bag, and (iv) return  it to the unmasked  designee.  
p. The Unmasked Designee can dispense the Other Supplies, as needed by [CONTACT_102]  
(refer to Section 4.4.3).  
q. If the Subject was randomized (a subject ID has been assigned in ORS) and needs to 
be exited during this visit, complete the Exit Visit as per Section 6.1.5.  
r. Complete  the forms  below  and transcribe  to the eCRFs:  
− Screening/Dispensing  Visit  Form  
− Exit Visit  Form  (to be used if the subject  is discontinued  after a subject  ID has been 
assigned in ORS)  
 
6.1.2 2-Week  Follow -up Visit  
The 2-Week  Follow -up Visit  will proceed  as follows:  
NOTE:  All VA measurements  MUST  be made  using  a phoropter.  
a. If a subject  misses  the scheduled  follow -up visit and cannot  be seen prior  to the start of 
the visit window for the next scheduled follow -up visit, then the visit is considered 
missed, and the subject must be exited from the study (see Section 3.2.3).  
b. Collect  the follo wing  lens wear  parameters  from  the subject:  
− Average  daily  wearing  time (since  last visit)  
− Average  hours  of comfortable  wear  (since  last visit)  
− Hours  lenses  worn  on the day of this visit 
− Did subject  replace  their lenses?  (If so, when)  
c. Complete  the Lens  Performance  Assessment  Form  (Study  Lenses  Performance  Rating 
Scales).  
d. Have the subject complete and initial the Symptoms/Complaints Form (Study Lenses 
Symptoms/Complaints Rating Scales), including use of rewetting drops.  
− Site personnel  will transcribe  this information  to the visit eCRF,  and will retain  the 
original in the study files.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794286] did not come to the visit wearing one or more study  lenses, go to step g. 
otherwise,  evaluate  the lenses  (while  on eye) and record  the following  assessments  into 
the subject’s source document:  
− High  contrast  distance  lens VA 
− Over -refraction  and distance  VA 
− Lens  wettability  
− Lens  discoloration  
− Lens  deposits  (type,  percent  and degree)  
− Lens  centration  
− Lens  movement  
− For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has 
decreased by 10 letters (0.2 logMAR) or more, explain.  
g. Perform  a slit lamp  examination  (remove  and store the lenses  if the subject  wore  lenses 
to the visit).  A lens case must be filled with Sensitive Eyes saline (NOT dispensed 
study solution) for storage of subject’s lenses during the exam. Record the results in 
the subject’s source document.  If a corneal i nfiltrate is noted fill out the Corneal 
infiltrate form.  
h. Record  and sketch  any scars  and slit lamp  findings  greater  than Grade  [ADDRESS_794287]’s 
source document.  
i. Return  the lenses  to the subject  to wear  until the next study  visit.  
j. If an unscheduled lens replacement is required, dispense a new pair of the subject’s  
habitual contact [CONTACT_599842] 6.1.6, k.  
k. If the subject  needs  to exit the study  at this visit,  complete  the Exit Visit  as per Section 
6.1.5.  
l. Complete  the forms  below  and transcribe  to the eCRFs:  
− 2-Week  Follow -up Visit  Form  
− Exit Visit  Form  (to be used if the subject  is discontinued  or exited  at this visit)  
m. If needed, dispense a new labeled reserve bottle of Test or Control product according 
to the subject’s ID number, and record in the subject’s individual Product 
Accountability Log. If needed, dispense any other supplies.  
 
6.1.3 1-Month  and 2-Month  Follow -up Visits 
The 1-Month  and 2-Month  Follow -up Visits  will proceed  as follows:  
NOTE:  All VA measurements  MUST  be made  using  a phoropter.  
 
a. If a subject  misses  either  the 1-Month  or 2-Month  scheduled  follow -up visit and cannot 
be seen prior  to the start of the visit window  for the next scheduled  follow -up visit,  then 
the visit is considered missed and subject must be exited from the study (see Section 
3.2.3)  
b. Collect  the following  lens wear  parameters  from  the subject:  
Study  #932  - Protocol  
Date:  13FEB2019  Page  23 of 65  
 − Average  daily  wearing  time (since  last visit)  
− Average  hours  of comfortable  wear  (since  last visit)  
− Hours  lenses  worn  on the day of this visit 
− Did subject  replace  their lenses?  (If so, when)  
c. Complete  the Lens  Performance  Assessment  Form.  (Study  Lenses  Performance  Rating 
Scales).  
d. Have  the subject complete,  and initial the  Symptoms/Complaints  Form (Study  Lenses 
Symptoms/Complaints Rating Scales), including use of rewetting drops.  
− Site personnel  will transcribe  this information  to the visit eCRF,  and will retain  the 
original in the study files.  
e. Collect any relevant medical treatment information, including any adverse events, on 
the [ADDRESS_794288] did not come to the visit wearing  one or more study  lenses, go to step g. 
Otherwise,  evaluate  the lenses  (while  on eye),  and record  the following  assessments  on 
the subject’s source documentation:  
− High  contrast  distance  lens VA 
− Over -refraction  and distance  VA 
− Lens  wettability  
− Lens  discoloration  
− Lens  deposits  (type,  percent,  and degree)  
− Lens  centration  
− Lens  movement  
− For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has 
decreased by 10 l etters (0.2 logMAR) or more, explain.  
g. Perform a slit lamp examination (remove the lenses if the subject wore lenses to the 
visit). Record and sketch any scars and slit lamp findings greater than Grade [ADDRESS_794289]’s  source  document.  If a corneal  infilt rate is noted  fill out the Corneal  infiltrate 
form.  
h. Collect  the worn  lenses  from  the subject  and return  all worn  study  lenses  to the Sponsor 
or designee using the return materials provided (refer to Section 4.4.3). Worn lenses 
will be returned  in lens cases  filled  with Bausch  + Lomb  Sensitive  Eyes  Saline  Solution.  
i. Dispense  a new pair of subject’s  habitual  lenses,  instruct  the subject  to insert  the lenses, 
and collect the following information in the subject’s source documentation:  
− Dispensed  lens type (brand),  sphere  power,  base curve  
− High  contrast  distance  lens VA 
− Over -refraction  and distance  VA 
− Lens  wettability  
− Lens  centration  
− Lens  movement  
Study  #932  - Protocol  
Date:  13FEB2019  Page  24 of 65  
 − For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has 
decreased by 10 letters (0.2 logMAR) or more, explain.  
j. If needed, dispense a new labeled reserve bottle  of Test or Control product according 
to the subject’s ID number, and record in the subject’s individual Product 
Accountability Log.  If needed, dispense any other supplies.  
k. If the subject  needs  to exit the study  at this visit,  complete  the Exit Visit  as per Section 
6.1.5.  
l. Complete  the forms  below  and transcribe  to the eCRFs:  
− 1-Month  or 2-Month  Follow -Up Visit  Form  
− Exit Visit  Form  (to be used if the subject  is discontinued  or exited  at this visit)  
6.1.4 3-Month  Follow -up 
The 3-Month  Follow -up will proceed  as follows:  
NOTE:  All VA measurements  MUST  be made  using  a phoropter.  
a. Collect  the following  lens wear  parameters  from  the subject:  
− Average  daily  wearing  time (since  last visit)  
− Average  hours  of comfortable  wear  (since  last visit)  
− Hours  lenses  worn  on the day of this visit 
− Did subject  replace  their lenses?  (If so, when)  
− Last date that lenses  were  worn  after cleaning  and storing  them  in study  solution  
− Number  of days on study  that the  subject did not use  the cleaning  and disinfecting 
solution  
− Number  of days on study  that the subject  did not wear  the study  lenses  
− Percentage of days on study that the subject used study solution and wore their 
lenses  on average (less than 80% = fewer than four out of five days, or 80% or 
more  = at least four out five days)  
b. Complete  the Lens  Performance  Assessment  Form  (Study  Lenses  Performance  Rating 
Scales).  
c. Have the subject complete Symptoms/Complaints Form (Study Lenses 
Symptoms/Complaints Rating Scales), including use of rewetting drops.  
− Site personnel  will transcribe  this information  to the visit eCRF,  and will retain  the 
original in the study files.  
d. Indicate if a Post -study Follow -up Visit is required and, if necessary, schedule the 
subject accordingly.  
e. Collect any relevant medical treatment information, including any adverse events, on 
the 3-Month  Follow -up Visit  Form , including  whether  a culture  may have been  taken.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794290] did not come to the visit wearing  one or more study  lenses, go to step g. 
Otherwise,  evaluate  the lenses  (while  on eye) and record  the following  assessments  on 
the subject’s so urce documentation:  
− High  contract  distance  lens VA 
− Over -refraction  and distance  VA 
− Lens  wettability  
− Lens  discoloration  
− Lens  deposits  (type,  percent,  and degree)  
− Lens  centration  
− Lens  movement  
− For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has 
decreased by 10 letters (0.2 logMAR) or more, explain.  
g. Perform a slit lamp examination (remove the lens es if the subject wore lenses to the 
visit). Record and sketch any scars and slit lamp findings greater than Grade [ADDRESS_794291]’s  source  document.  If a corneal  infiltrate  is noted  fill out the Corneal  infiltrate 
form.  
h. Collect all worn dispensed lenses and used and unused bottles of study solution from 
the subject  and return  all to the Sponsor  or designee  using  the return  materials  provided 
(refer  to Section  4.4.3).  Worn  lenses  will be returned  in lens cases  filled  with Bausch  + 
Lomb Sensitive Eyes Saline Solution.  It is important that the site personnel do not 
observe the contents of the study solution return bag.  
i. Complete  the Exit Visit  as per Section  6.1.5.  
j. Complete  the forms  below  and transcribe  to the eCRFs:  
− 3-Month  Follow -up Visit  Form  
− Exit Visit  Form  (if there  is an ongoing  AE at  the time of the [ADDRESS_794292] Study Visit instead)  
 
6.1.5 Exit Visit  
The Exit Visit  will proceed  as follows:  
a. Indicate status of the subject on the Exit  Visit  Form. If the status is “Discontinued” or 
“Non -dispensed,” indicate the (one) PRIMARY exit reason for each eye on the Exit 
Visit Form.  
b. For all subjects,  complete  an exit ocular  examination  without  lenses  on the eyes.  Collect 
the following assessments:  
− Spherocylindrical  refraction  
− High  contrast  distance  BSCVA  
− Keratometry  
Study  #932  - Protocol  
Date:  13FEB2019  Page  26 of 65  
 c. For each eye: 
− Compare  the final visit high contrast  distance  BSCVA  to the high contrast  distance 
BSCVA  obtained  at the Screening/Dispensing  Visit.  If the VA has decreased  by 10 
letters (0.2 logMAR) or more, explain.  
− Compare the final visit keratometry readings to the Screening/Dispensing Visit 
keratometry readings. If there is a change of 1.[ADDRESS_794293]  all worn  dispensed  lenses  and Study Kits (if not collected  previously)  from  the 
subject and return all to the Sponsor or designee using the return materials provided 
(refer  to Section  4.4.3).  Worn  lenses  will be returned  in lens cases  filled  with Bausch  + 
Lomb Sensitive Eyes Saline Solution.  
 
6.1.[ADDRESS_794294] visit within the 
scheduled  visit interval  will be used for completion  of the protocol  required  scheduled  visit 
eCRF.  Data  from  any additional  visits  within  a scheduled  visit interval  will be captured  on 
an Unscheduled Visit eCRF.  
Unscheduled  Visits  will proceed  as follows:  
NOTE:  All VA measurements  MUST  be made  using  a phoropter.  
a. Indicate  the reason  for the Unscheduled  Visit.  
b. If the subject  is experiencing  problems,  complete  the Unscheduled  Visit  Form.  
c. If this visit is to dispense study  materials only and the subject is not experiencing any 
problems, refer to Section 6.1.8.  
d. Collect  the following  lens wear  parameters  from  the subject:  
− Average  daily  wearing  time (since  last visit)  
− Average  hours  of comfortable  wear  (since  last visit)  
− Hours  lenses  worn  on the day of this visit 
− Did subject  replace  their lenses?  (If so, when)  
 
e. Complete  the Lens  Performance  Assessment  Form  (Study  Lenses  Performance  Rating 
Scales).  
f. Have the subject complete and initial the Symptoms/Complaints Form (Study Lenses 
Symptoms/Complaints), including use of rewetting drops.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  27 of 65  
 − Site personnel  will transcribe  this information  to the visit eCRF,  and will retain  the 
original in the study files.  
g. Collect any relevant medical treatment information, including any adverse events, on 
the Unscheduled Visit Form, including whether a culture may have been taken.  
h. If the subject did not come to the visit wearing one or more study lenses, go to step i. 
Other wise,  evaluate  the lenses  (while  on eye) and record  the following  assessments  on 
the source documentation:  
− High  contrast  distance  lens VA 
− Over -refraction  and distance  VA 
− Lens  wettability  
− Lens  discoloration  
− Lens  deposits  (type,  percent  and degree)  
− Lens  centration  
− Lens  movement  
− For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has 
decreased by 10 letters (0.2 logMAR) or more, explain.  
i. Perform a slit lamp exa mination (remove the lenses if the subject wore lenses to the 
visit). Record and sketch any scars and slit lamp findings greater than Grade [ADDRESS_794295]’s source document and transcribe this information to the visit eCRF.  If a 
corneal infiltrate is not ed fill out the Corneal infiltrate form.  
j. If additional  study  solution  is required  at this visit,  dispense  a new labeled  reserve  bottle 
of Test or Control product according to the subject’s ID number, and record in the 
Product Accountability  Log. If a new Study  Kit is required, log  into ORS to dispense 
a new Study Kit (refer to Section 4.4.3) to the subject according to ORS notifica tion 
email and record in the Product Accountability.  
k. If an unscheduled lens replacement is required at this visit, dispense a new pair of 
subject’s habitual lenses and collect the following information in the subject’s source 
documentation:  
− Primary  (one)  reason  for replacement  
− Dispensed  lens type (brand),  sphere  power,  base curve  
− High  contrast  distance  lens VA 
− Over -refraction  and distance  VA 
− Lens  wettability  
− Lens  discoloration  
− Lens  centration  
− Lens  movement  
− For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has 
decreased by 10 letters (0.2 logMAR) or more, explain.  
l. If Study Lenses were replaced, collect the worn lenses from the subject and return all 
worn  study  lenses  to the Sponsor  or designee  using  the return  materials  provided  (refer 
to Section  4.4.2).  Worn  lenses  will be returned  in lens cases  filled  with Bausch  + Lomb 
Sensitive Eyes Saline Solution.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794296]  needs  to exit the study  at this visit,  complete  the Exit Visit  as per Section 
6.1.5.  
n. Complete  the form(s)  listed  below  and transcribe  to the eCRF  as appropriate:  
− Unscheduled  Visit  Form  
− Exit Visit  Form  (to be used if the subject  is discontinued  or exited  at this visit)  
6.1.7 Missed  Visits  
Missed  Visits  will be handled  as follows:  
a. If a subject misses any scheduled follow -up visit and cannot be seen prior to the start 
of the visit range  for the next scheduled  follow -up visit,  the visit is considered  missed, 
and the subject must be exited (see Section 3.2.3).  
 
6.1.[ADDRESS_794297]  Dispensing  Only  Visits  will proceed  as follows:  
a. If a subject is seen for resupply or replacement of study materials only, a complete 
exam is not required, as long as the subject is not experiencing any problems. If any 
assessment is performed, then an Unscheduled Visit Form must be completed (see 
sectio n 6.1.6).  
b. If additional Study Solution is required at this visit, go to Unscheduled Visit Section 
6.1.6, j.  
c. If a lens replacement  is required,  go to Unscheduled  Visit  Section  6.1.6,  k. 
 
6.[ADDRESS_794298]-study  Follow -up 
NOTE:  All VA measurements  MUST  be made  using  a phoropter.  
a. If a subject  requires  further  follow -up upon  discontinuation  or completion  of the study, 
the Investigator must schedule post -study follow -up visits, as necessary.  The 
Investigator is required to follow the subject until the condition no longer w arrants 
further follow -up for study purposes. A Post -study Follow -up Visit eCRF must be 
completed for each of these visits.  
b. Perform a slit lamp examination (remove the lenses if the subject wore lenses to the 
visit). Record and sketch any scars and slit la mp findings greater than Grade [ADDRESS_794299]’s source document and transcribe to the eCRF as appropriate.  If a corneal 
infiltrate is noted fill out the Corneal infiltrate form.  
c. Complete an ocular examination without lenses on the eyes, including 
spheroc ylindrical refraction and high contrast distance BSCVA.  
d. Compare the high contrast distance BSCVA to the high contrast distance BSCVA 
obtained at the Screening/Dispensing  Visit. If the VA has decreased by  10 letters (0.2 
logMAR) or more, explain.  
e. If the subject is exiting  the study  at this visit,  complete  Exit Visit  as per Section  6.1.5.  
f. Complete  the form(s)  listed  below  and transcribe  to the eCRF  as appropriate:  
− Post-study  Follow -up Visit  Form  
− Exit Visit  Form  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794300] been exited. Sponsor approval is required prior to IRB 
notification.  
 
6.3.2 Early  Study  Termination/Suspension  
If during the study it becomes evident to the Sponsor that the study should be stopped 
prematurely or placed on hold, the  study will be terminated and appropriate notification 
will be given to the Investigator(s), IRBs, and FDA, as applicable. Bausch + Lomb will 
instruct the Investigators to stop/restart dispensing study materials and will arrange for 
study closeout, if appl icable, at each site.  
 
6.4 Concomitant  Medications/Therapy  
Other  ocular  solutions,  medications  or drops  are not allowed  to be used by [CONTACT_599843]. Use of other contact [CONTACT_599844].  
Ocular medications, systemic or topi[INVESTIGATOR_599818], in the Investigator’s opi[INVESTIGATOR_1649], 
could potentially affect ocular physiology  or lens performance are also prohibited, unless 
medically  necessary  during  the course  of the study.  If used during  the course  of the study, 
these medications must be recorded in the source document and the appropriate eCRF.  
 
 
6.[ADDRESS_794301]  who does not follow 
instructions to a degree that, in the Sponsor or Investigator's opi[INVESTIGATOR_1649], jeopardizes the 
subject's well -being or the validity of the study, must be discontinued.  
 
6.6 Protocol  Deviations  
The date of and reason for deviations (failure to comply with the protocol, eligibility or 
randomization errors, not done visits, out of window study visits, worn lenses not 
returned,  habitual  lenses  not worn  daily,  etc.) will be documented  in all cases.  Significant 
or major protocol deviations impacting the safety of the subject or the integrity of the 
study must be reported by [CONTACT_599845]. 
Reporting of all other protocol deviations must adhere to the require ments of the 
governing IRB.  
A subject may continue to participate until the end of the study, unless the protocol 
deviations put the subject at risk, the subject’s condition requires that the subject be 
discontinued  from  the study  or other  sections  of this protocol  state that the subject  must  be 
discontinued due to the deviation (see Section 3.2.3).  
Study  #932  - Protocol  
Date:  13FEB2019  Page  30 of 65  
 7.0 ADVERSE  EVENTS  
 
7.1 Adverse  Event  Definitions  
For the purposes of this study, reportable adverse events (AEs) include ocular AEs and 
non-ocular seriou s adverse events (SAEs). All AEs will be classified first for seriousness 
and significance  and then as to whether  or not they are an adverse  device  effect  (ADE),  an 
anticipated serious adverse device effect (ASADEs) or an unanticipated serious adverse 
device  effect  ([LOCATION_003]DEs).  AEs,  ADEs,  ASADEs,  [LOCATION_003]DEs,  SAEs,  Significant  Non-Serious 
AEs and Non -Significant Non -Serious AEs are defined as follows:  
 
7.1.1 Adverse  Event  (AE)  
Any untoward  medical  occurrence,  unintended  disease  or injury,  or untoward  clinical  signs 
(including abnormal laboratory findings) in a subject, user, or other persons, whether or 
not related  to the investigational  medical  device.  This definition  includes  events  not related 
to the investigational  medical  device,  comparator,  or the procedures  involved.  For users  or 
other persons, this definition is restricted to events not related to investigational medical 
devices.  
Throughout the course of this study all efforts will be made to remain alert to reportable 
AEs. If an AE occurs the first concern will be the safety of the subject and appropriate 
medical intervention will be made.  
AEs should be first assessed for seriousness and significance a nd then differentiated for 
device related and non -device related.  
All reportable AEs occurring after signing of informed consent and through the subject’s 
end of participation in the study must be reported. All reportable AEs must be followed 
until the eve nt resolves or stabilizes.  
Applicable AEs should be photo documented and communicated to the Medical Monitor 
in electronic form.  
 
7.1.[ADDRESS_794302]  (ADE)  
An adverse device effect is an AE that is assessed to be related to the use of an 
investigational  medical  device.  This definition  includes  AEs resulting  from insufficient  or 
inadequate  instructions  for use; deployment,  implantation,  installation,  or operation;  or any 
malfunction of the investigational medical device. This definition also includes any  event 
resulting from use error or from intentional misuse of the investigational medical device.  
 
[IP_ADDRESS]  Anticipated  Serious  Adverse  Device  Effect  (ASADE)  
An anticipated seri ous adverse device effect (ASADE) is an ADE that first meets the 
serious  criteria  (see Section  7.1.3)  or significant  non-serious  criteria  (see Section  7.1.4)  and 
which, by  [CONTACT_5942], incidence, severity or outcome, has been previously identified in the 
investigational plan or application (including a supplementary  plan or application) and/or 
in the risk analysis report. ASADEs include:  
• Corneal  Ulcer  (infectious  or non-infectious)  
• Keratitis  
• Sensitivity  to light (photophobia)  
• Excessive  eye secretions  including  mucopurulent  discharge  
Study  #932  - Protocol  
Date:  13FEB2019  Page  31 of 65  
 • Blurred  vision,  rainbows  or halos  around  objects  
• Poor  visual  acuity  (reduced  sharpness  of vision)  
• Moderate  to severe  eye pain not relieved  by [CONTACT_599846] 
[IP_ADDRESS]  Unanticipated  Serious  Adverse  Device  Effect  ([LOCATION_003]DE)  
An unanticipated serious adverse device effect ([LOCATION_003]DE) is an ADE that first meets the 
serious  criteria  (see Section  7.1.3)  or significant  non-serious  criteria  (see Section  7.1.4)  and 
has an effect on health or safety or any life -threatening problem or death caused by, or 
associated with, a device if that effect, problem or death was not previously identified in 
nature,  severity  or degree  of incidence  in the investigational  plan or application  (including 
a supplementary  plan or application),  or any other  unanticipated  serious problem associated 
with a device that relates to the rights, safety, or welfare of subjects.  
 
7.1.3 Serious  Adverse  Event  (SAE)  
An AE that: 
o Led to death;  
o Led to serious  deterioration  in the health  of the subject,  that resulted  in: 
‒ A life-threatening  illness  or injury;  or 
‒ A permanent  impairment  of a body  structure  or a body  function  (e.g., 
blindness); or  
‒ Inpatient  or prolonged  hospi[INVESTIGATOR_059];  or 
‒ Medical or surgical intervention to prevent life -threatening illness or 
injury  or permanent  impairment  to a body  structure  or a body  function;  
o Led to fetal distress,  fetal death,  or a congenital  abnormality  or birth  defect.  
Note: A planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure 
required  by [CONTACT_760],  without  serious  deterioration  in health,  is not considered 
an SAE.  
Serious  adverse  events  are also those  events  that result  in, or have  potential  to cause,  either 
permanent impairment of an ocular function or damage to an ocular structure and may 
necessitate medical or surgical intervention.  
Serious  adverse  events  may include  any hazardous,  sight -threatening  conditions  occurring 
after exposure to the test art icle, including the following:  
• A presumed  infectious  ulcer  (defined  as a progressive  erosion  of the corneal 
tissue). For the purposes of reporting, this includes:  
o Central  or para-central  location;  
o Penetration  of Bowman’s  membrane;  
o Infiltrate  ≥2 mm diameter;  
o Associated  with iritis;  
o Associated  with any increase  in intraocular  pressure;  
o Culture  positive  for microorganisms;  
o Increasing  size or severity  at subsequent  visits;  
Study  #932  - Protocol  
Date:  13FEB2019  Page  32 of 65  
 NOTE: Signs of a presumed infectious corneal ulcer may include irregular focal 
infiltrates,  active  lesions  with raised  edges,  significant  diffuse  infiltration,  anterior 
corneal to mid -stromal involvement, erosion with overlying staining, conjunctival 
and l id edema, anterior chamber reaction (iritis), and severe bulbar and limbal 
redness. Symptoms associated with a presumed infectious ulcer (microbial 
keratitis) may include pain of rapid onset, severe redness, purulent or 
mucopurulent discharge, tearing, and  photophobia.  
• Any central  or paracentral  (within  6 mm of cornea)  corneal  event  that results  in 
permanent opacification (such as corneal scar or vascularization);  
• Any serious  adverse  ophthalmic  events  including  hypopyon  and/or  hyphema;  
• Any neovascularization  within  the central  6 mm of the cornea;  
• Permanent  loss of ≥2 lines  of BSCVA;  
• All cases  of iritis.  
7.1.4 Significant  Non-Serious  Adverse  Events  
A significant non -serious adverse  event is  an AE that does  not meet the  serious  criteria,  is 
considered significant by [CONTACT_1034], and requires expedited reporting. These events 
include:  
• Peripheral  non-progressive  non-infectious  corneal  ulcers;  
• All symptomatic  corneal  infiltrative  events;  
• All cases  of corneal  staining  greater  than or equal  to Grade  3; 
• A temporary  loss of two or more  lines  of BSCVA  (for greater  than or equal  to 2 
weeks);  
• Neovascularization  cases  Grade  2 or greater;  
• Any ocular  event  that necessitates  temporary  lens discontinuation  of greater  than 
or equal to 2 weeks.  
 
7.1.5 Non-Significant  Non-Serious  Adverse  Events  
A non -significant non -serious adverse event may include but are not limited to the 
following and does not require expedited reporting:  
• Bacterial  Conjunctivitis;  
• Viral  Conjunctivitis;  
• Allergic  Conjunctivitis;  
• Corneal  Edema;  
• Contact  [CONTACT_599847][INVESTIGATOR_599819];  and, 
• Loss  of Contrast  Sensitivity  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794303] of care.  
For purposes of this study, the Sponsor requests that cultures should be obtained in cases 
of corneal ulcer or suspected ocular infection, unless medically contraindicated. Cultures 
should be taken from the cul -de-sac, lower eyelid margin, and the corneal lesion (if 
applicable). The required culturing techniques are outlined in Appendix B.  
When a culture i s obtained, the contact [CONTACT_599848].  
Microbial  data generated  from  returned  subject  supplies  (e.g. lenses,  lens cases,  and/or  lens 
case solutions)  are for information  only.  Because  microbes  may be introduced  into subject 
supplies during use, recovery of microbes from returned subject supplies cannot be 
presumed to indicate etiology or direction of organism transmission.  
The ocular cultures, along with the associated contact [CONTACT_145924], will 
be se nt to the local clinical laboratory designated by [CONTACT_240377]. The clinical 
laboratory will report the culture results to the Investigator who will record the results in 
the eCRF.  
 
7.[ADDRESS_794304] determine if the event is 
serious (refer to Section 7.1.3 for criteria) and/or significant (refer to Sections 7.1.4 and 
7.1.5) and then assess the severity of symptoms and the relationship of the event to the 
study device using the following guidelines:  
 
7.3.1 Severity  
• Mild: Subject awareness of a sign or symptom that is easily tolerated, 
requires  no treatment,  and does not interfere  with subject’s  daily  activities.  
• Moderate: Subject awareness of a s ign or symptom which may be a low 
level  of concern  to the subject  and may interfere  with daily  activities  but can 
be relieved by [CONTACT_119106].  
• Severe: A sign or symptom that interrupts the subject’s daily activity and  
requires systemic therapy or other treatment  
 
7.3.2 Relationship  to Study  Device  and/or  Rewetting  Drops  
• Related:  There  is at least a reasonable  possibility  that the AE is related  to 
the study dev ice (study solution) and/or rewetting drops. Reasonable 
possibility  means  that there  is evidence  to suggest a  causal relationship  or 
association between the study device and/or rewetting drops and the AE. 
Also referred to as an ADE.  
• Unrelated: There is lit tle or no reasonable possibility  that the AE is related 
to the study  device  (study  solution)  and/or  rewetting  drops.  This assessment 
implies that the AE has no evidence to suggest either a causal relationship  
Study  #932  - Protocol  
Date:  13FEB2019  Page  34 of 65  
 or association  to the study  device  and/or  Rewetting  Drops  and a more  likely 
or certain alternative etiology exists.  
 
7.4 Procedures  for Reporting  SAEs  and Significant  Non-Serious  Adverse  Events  
An AE classified  as a SAE  or a Significant  Non-Serious  AE requires  expeditious  handling 
and reporting to the Sponsor to comply with regulatory requirements, as follows:  
• The event must be reported to the Medical Monitor within 24 hours of the 
Investigator’s  awareness  of the event  via facsimile/email  transmission  on a 
paper SAE or Sign ificant Non -Serious AE Report Form signed by [CONTACT_3786].  
• The Medical  Monitor  will email  a copy  of the form  (within  24 hours)  to 
 
 
• Investigators should not wait to receive additional information to fully 
document  the event  before initially  notifying  the Medical  Monitor  of an SAE 
or a Significant Non -Serious AE. Additional relevant information such as 
hospi[INVESTIGATOR_599820].  
• The Investigator  should  take all appropriate  measures  to ensure  the safety  of 
the subjects: notably, he/she should follow a subject with an SAE or 
Significant  Non-Serious  AE until the event  has resolved  or the condition  has 
stabilized. This may  imply that follow -up will continue after the subject has 
left the study, and that additional evaluations may be requested by [CONTACT_429].  
• Ensure  that the subject's  identity  is protected  and the subject's  identifiers  in the 
clinical trial are properly menti oned on the form.  
• BEGIN  TREATMENT  OF THE  AE IMMEDIATELY  BY A SUITABLY 
LICENSED EYE CARE PROFESSIONAL.  
• Continue to update the paper SAE or Significant Non -Serious AE Report 
Form, if applicable, each time the subject is seen during the management of 
the event and at resolution of the event.  All updated report forms should be 
submitted to the Medical Monitor who will distribute the reports as stated 
above. Whenever possible, it is suggested that the Investigator take 
photographs  of all applicable  AEs and forward  them  to the Medical  Monitor.  
• Events  requiring  medical  treatment  will be evaluated  by [CONTACT_1034].  Upon 
review of the medical treatment, Bausch + Lomb Clinical Operations  

Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794305]  further  information 
concerning the treatment.  
• Report all [LOCATION_003]DEs to the reviewing IRB within 10 working da ys following 
awareness  of the [LOCATION_003]DE  or according  to the established  reporting  procedures 
of the IRB, whichever is shorter.  
• Submit all bills, prescription receipts, and culture reports/fees related to the 
AE to the Bausch + Lomb Clinical Operations.  Expense incurred for study 
related  medical  treatment  will be paid by [CONTACT_59268]  +Lomb  Clinical  Operations.  
 
7.4.[ADDRESS_794306], and report via applicable forms any complaints/ 
deficiencies or malfunctions experienced with the study solution during this trial to the 
Medical Monitor promptly. The Sponsor and Medical Monitor shall review all device  
deficiencies and, upon the Sponsor’s request, Investigators must supply any additional 
information related to the safety reporting of a particular event.  
Report  device  deficiencies  within  24 hours  of knowledge  to: 
The Medical  Monitor  will distribute,  within  24 hours  of knowledge,  all device  deficiencies 
to the Sponsor including:  
The Sponsor shall review a ll device deficiencies and determine and document in writing 
whether  they could  have  led to an SAE.  In the event  of a disagreement  between  the Sponsor 
and the Investigator(s),  the Sponsor  shall  communicate  both opi[INVESTIGATOR_599821].  
 
7.4.[ADDRESS_794307] visit, in a manner such that risk of 
contraceptive failure is minimized. Abstinence is allowed as a birth control method.  

Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794308]  they might  be pregnant  (eg. missed  or 
late menstrual period). Female subjects who become pregnant during the study will be 
followed until completion of pregnancy. Every effort will be made to obtain the health 
status of  the mother  and infant or  fetus (in cases of miscarriage  or therapeutic  abortion)  at 
term. Pregnancy itself is not considered an AE.  
All confirmed pregn ancies must be reported on a paper Pregnancy Report Form and 
submitted to the Medical Monitor via facsimile or email transmission within 24  hours of 
the Investigator’s awareness of the pregnancy.  The Medical Monitor will distribute the 
completed form to th e Sponsor as per the distribution list in Section 7.4.  
All pregnancies will be followed until outcome even after study  closure.  The outcome of 
all pregnancies  will be reported  on a paper  Pregnancy  Outcome  Report  Form  and submitted 
to the Medical Monitor vi a facsimile or email transmission once the outcome is learned. 
The Medical Monitor will distribute the completed form to the Sponsor as per the 
distribution list in Section 7.4.  
Although pregnancy occurring in a clinical study is not considered to be an AE  or SAE, 
any pregnancy  complication,  spontaneous  abortion,  or elective  termination  of a pregnancy, 
for medical reasons, will be recorded as an SAE. Any serious complication or event 
resulting from the pregnancy should be reported to the Medical Monitor within [ADDRESS_794309]  for reporting  pregnancies  and pregnancy  outcomes  are: 

Study  #932  - Protocol  
Date:  13FEB2019  Page  37 of 65  
 8.0 STATISTICAL  METHODS  
 
8.1 Study  Endpoints  
 
8.1.1 Primary  Effectiveness  Endpoints  
a. Overall  comfort  averaged  over all follow -up visits.  
b. Dryness  averaged  over all follow -up visits.  
c. Lens  deposits  at all follow -up visits.  
 
8.1.2 Secondary  Effectiveness  Endpoints  
There  are no secondary  effectiveness  endpoints.  
 
8.1.3 Primary  Safety  Endpoint  
Slit lamp  findings  greater  than Grade  2. 
 
8.2 Hypotheses  
 
8.2.1 Overall  Comfort  Averaged  Over  All Follow -up Visits  
The null hypothesis ( HO) is that the difference in mean overall comfort (test group mean 
[µT] minus standard group mean [ µS]) is less than or equal to negative five points. The 
alternative hypothesis ( H1) is that the difference is greater than negative five points.  
HO: µT − µS ≤ −5 
H1: µT − µS > −5 
8.2.2 Dryness  Averaged  Over  All Follow -up Visits  
The null hypothesis  (HO) is that the difference  in mean  dryness  score  (test group  mean  [µT] 
minus standard group mean [ µS]) is less than or equal to negative five points. The 
alternative hypothesis ( H1) is that the difference is greater than negative five points.  
HO: µT − µS ≤ −5 
H1: µT − µS > −5 
8.2.3 Lens  Deposits  at All Follow -up Visits  
The null hypothesis  (HO) is that the difference  in the proportion  of eyes with None  or Light 
ratings of  lens deposits  at all  Follow -up Visits  (test group  proportion  [rrT] minus  standard 
group  proportion  [rrS]) is less than or equal  to -0.1 (-10%).  The alternative  hypothesis  (H1) 
is that the difference is greater than -0.1 (-10%).  
HO: rrT − rrS ≤ −0.1  
H1: rrT − rrS > −0.1  
Study  #932  - Protocol  
Date:  13FEB2019  Page  38 of 65  
 8.2.4 Slit Lamp  Findings  Greater  than  Grade  2 
The null hypothesis ( HO) is that the difference in the proportion of eyes with slit lamp 
findings  greater  than grade  2 (test group  proportion  [rrT] minus  standard  group  proportion 
[rrS]) is greater than or equal to 0.05 (5%). The alternative hypothesis ( H1) is that the 
differenc e is less than 0.05 (5%).  
HO: rrT − rrS ≥ 0.05 
H1: rrT − rrS < 0.[ADDRESS_794310]  deviations  and proportions  were  obtained  from  Bausch  + Lomb 
Study #872.[ADDRESS_794311]’s eyes will be independent.  
Sample  size calculations  were  completed  using  nQuery  Advisor®  7.[ADDRESS_794312] 
96.82% power to reject the null hypothesis that the test is not non -inferior to the standard 
(the difference in means, µT - µS, is -5 or farther from zero in the same d irection) in favor 
of the alternative hypothesis that the test is non -inferior, assuming that the expected 
difference in means is [ADDRESS_794313] 
96.62% power to reject the null hypothesis that the test is not non -inferior to the standard 
(the difference in means, µT - µS, is -5 or farther from zero in the same direction) in favor 
of the alternative hypothesis that the test is non -inferior, assuming that the expected 
difference in means is [ADDRESS_794314] deviation is 14.0.  
 
8.3.3 Lens  Deposits  
With  226 eyes in each group,  the lower  limit of  the observed  one-sided  97.5%  confidence 
interval will be expected to exceed -0.100 with 97 .38% power when the Standard 
proportion,  πS, is 0.[ADDRESS_794315] expected  proportion,  πT, is 0.925;  results  are based  on 
100,[ADDRESS_794316] the 
confidence interval.2 
 
8.3.4 Slit Lamp  Findings  Greater  than  Grade  2 
With  226 eyes in each group,  the upper  limit of  the observed  one-sided  97.5%  confidence 
interval will be expected to be less than 0.050 with 99.00% power when the Standard 
proportion, π S, is 0.[ADDRESS_794317] expected proportion, π T, is 0.005; results are based 
on [ADDRESS_794318] the 
confidence interval.2 
Study  #932  - Protocol  
Date:  13FEB2019  Page  39 of 65  
 8.3.5 Overall  Power  
If the four primary endpoints are independent, the overall power of the study  is 96.82% x 
96.62% x 97.38% x 99.00% = 90.18%.  
 
8.3.6 Enrollment  Target  
Allowing for up to 10% losses, the enrollment target in each treatment group will be  
r113 ÷ (1 − 0.1) 1 = 126. Consequently,  the total enrollment  target  will be approximately 
252 subjects (504 eyes).  
 
8.4 Randomization  
Subjects  will be randomized  to one of two treatment  arms  in a 1:[ADDRESS_794319] solution 
or Control solution for the duration of the study.  Randomization will be managed using 
ORS.  The randomization will be stratified by  [CONTACT_240380].  The 
lens group will be determined by [CONTACT_748]’ habitual lens material at baseline and will 
be one of the groups shown in Table 1 above (page 9).  
Efforts will be made to enroll subjects in at least four of the len s strata within each site to 
minimize  confounding  between  site and lens strata.  It should  be noted  that while  the target 
enrollment for each lens strata is approximately 50 subjects (approximately 25 per 
treatment arm), some lens strata may be difficult to  enroll.  
An unmasked statistician who is not otherwise involved in the trial will create the 
randomization schedule.  
 
8.5 Study  Populations  
 
8.5.1 Intent -to-Treat  (ITT)  Population  
The ITT Population will consist of all randomized subjects for subject level summaries 
and, for eye level summaries, both of their eyes. Subjects will be included in ITT 
Population summaries according to the treatment group to which they were randomly 
assigned.  
 
8.5.2 Per Protocol  (PP)  Population  
The PP population will be the primary population used for analysis of the primary 
effectiveness endpoints.  The PP Population will consist of all ITT Population subjects 
without important (major) protocol deviations for s ubject level summaries and, for eye 
level  summaries,  both of their eyes.  Important  protocol  deviation  categories  are defined  in 
Section 8.6.4 below (page 41). Subjects will be included in PP Population summaries 
according to the treatment group to which they were randomly assigned.  The PP 
population will be determined prior to study unmasking.  
 
8.5.[ADDRESS_794320] treatment group.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  40 of 65  
 8.6 Statistical  Analysis  
 
8.6.1 Methods  of Analysis  
 
[IP_ADDRESS]  General  Methods  
Continuous data will be summarized using descriptive statistics: sample size (n), mean, 
standard deviation (SD), median, minimum and maximum. Categorical data will be 
presented using the total counts for each category and corresponding percentages. The 
denominator for each percentage will be the number of subjects or eyes with non -missing 
data at the given visit for each respective study treatment, unless otherwise indicated.  
As is customary for contact [CONTACT_599849], eyes will be treated as independ ent 
sampling units in eye level analyses unless otherwise noted.  
Further details will be provided in a separate statistical analysis plan which will be 
completed and approved prior to unmasking of the treatment assignments.  
 
[IP_ADDRESS]  Overall  Comfort  
At each  follow -up visit,  overall comfort will be  assessed  for each eye on a scale  from [ADDRESS_794321] favorable response. For each eye, mean overall comfort 
over all follow -up visits will be computed as the average of the non -missing values over 
all scheduled follow -up visits. Missing data will not be imputed for the prim ary analysis. 
Mean overall comfort over all follow -up visits will be summarized at the eye level by 
[CONTACT_599850] a table. A one - 
sided lower 97.5% confidence limit around the difference in means between the test and 
control  treatment  groups,  computed  using  an analysis  of variance  model  including  the fixed 
factor of treatment and the fixed blocking factor of site, will be displayed. If the lower 
confidence limit is greater than -5.0, then the null hypothesis that the test solution is not 
non- inferior will be rejected, and the test solution will be statistically successful in this 
outcome.  
As a sensitivity  analysis,  the ITT Population  will be analyzed  for this endpoint.  Summaries 
by [CONTACT_139679]  a confidence  interval around  the difference  in means  will be  provided  as 
described above using the available data. Twenty -five imputations of missing overall 
comfort  data will be produced  using  the Markov  chain  Monte  Carlo  (MCMC)  method  with 
a seed of [PHONE_12432]. The variables used to create the imputed datasets will be the 
randomized treatment assignments (categorical), the subject identification numbers 
(categorical), and the overall comfort scores observed at each scheduled visit. The 
differences and standard errors estimated by [CONTACT_599851].  
 
[IP_ADDRESS]  Dryness  
At each follow -up visit, dryness will be assessed for each eye on a scale from [ADDRESS_794322] fa vorable response. Dryness will be analyzed using the 
methods described above for overall comfort. The seed for multiple imputation will be 
[PHONE_12433].  
 
[IP_ADDRESS]  Lens  Deposits  
At each follow -up visit, lens deposits degree will be assessed for each eye as none, light , 
medium,  or heavy.  Using  only the non-missing  observations  from  scheduled  follow -up 
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794323]  to the maximum  observed 
grade  of Deposits  at All Follow -up Visits  (None  or Light,  Medium  or Heavy).  Missing  data 
will not be imputed  for the primary  analysis.  Maximum  Deposits  over All Follow -up Visits 
(None  or Light,  Medium  or Heavy)  will be summarized  at the eye level  by [CONTACT_599852] a table.  A one-sided  lower  97.5% 
confidence  limit  around  the difference  in None  or Light  Deposits  proportions  between  the 
test and control treatment groups will be constructed using the Newcombe -Wilson score 
method.2 If the lower  confidence  limit  is greater  than -10.0%,  then the null hypothesis  that 
the test solution  is not non-inferior  will be rejected,  and the test solution  will be statistically 
successful in this outcome.  
As a sensitivity  analysis,  the ITT Population  will be analyzed  for this endpoint.  Summaries 
by [CONTACT_139679]  a confidence  interval around  the difference  in means  will be  provided  as 
described above using the available data. The effects of missing data will be explored by 
[CONTACT_599853] -case i mputation scenarios. If the statistical conclusion 
differs between the best and worst -case scenarios, then a tippi[INVESTIGATOR_599822].  
 
[IP_ADDRESS]  Graded  Slit Lamp  Findings  > Grade  [ADDRESS_794324] to  findings  greater  than grade  2 at any 
visit (Absent, Present). Missing data will not be imputed. Greater than grade 2 findings 
(Absent, Present) will be summarized at the eye level by [CONTACT_599854] a table.  A one-sided  upper  97.5%  confidence  limit 
around the difference in “Present” proportions between the test and control treatment 
groups will be constructed using the Newcombe -Wilson score method.2 If the upper 
confidence  limit  is less than 5.0%,  then the null hypothesis  that the test solution  is not non- 
inferior  will be rejected,  and the test solution  will be statistically  successful  in this outcome.  
 
8.6.[ADDRESS_794325]  Discontinuation  
The reasons  for study  discontinuation  will be summarized  by [CONTACT_599855]. Details of discontinued eyes will be also listed by [CONTACT_3148].  
 
8.6.4 Protocol  Deviations  
Important  (major)  protocol  deviations  will be summarized  by [CONTACT_599856] a table.  
Categories  of important  protocol deviations  will include  the following,  which  will be 
derived via data entered on the case report forms.  
• Ineligibility  
• Not dispensed  study  treatment  
• Misrandomization  
Study  #932  - Protocol  
Date:  13FEB2019  Page  42 of 65  
 • Dispensing  of the incorrect  solution  
• Dispensing  and use of lenses  from  the incorrect  lens group  
• Use of medications that could potentially affect any of the primary effectiveness 
endpoints  
• Failure to comply with the procedures used to assess the primary effectiveness 
endpoints,  such as missing  the scheduled  visit or failing to complete  the procedure 
in accordance with instructions  
Additional  important  protocol  deviation  categories  may be added  prior  to unmasking. 
Important (major) protocol deviations will also be displayed in a listing.  
8.6.[ADDRESS_794326]  lens solution  trials,  treatment  exposure  will not be evaluated.  
 
8.6.7 Missing  Data  
Imputation of missing data is not conservative in a non -inferiority analysis setting. 
Therefore, primary effectiveness analyses will be completed using the PP Set without 
imputation of missing data.  
Sensitivity analyses of data from the ITT Set with missin g data imputation are described 
in Section 8.6.1 above. Unless otherwise specified in the protocol or statistical analysis 
plan, missing data will not be imputed.  
 
8.6.8 Interim  Analyses  
No interim  analyses  are planned.  
 
9.0 DATA  QUALITY  ASSURANCE  
 
9.1 Study  Monitoring  
Bausch + Lomb  Clinical Operations representatives  must be allowed to  visit all study  site 
locations to assess the data, quality, and study integrity in a manner consistent with 
applicable   health   authority   regulations   and  the  procedures   adopted   by 
[CONTACT_59268] + Lomb Clinical Operations.  
Prior to the start of the study, member(s) of the Bausch + Lomb Clinical Operations, 
Clinical  Affairs,  and Global  Regulatory  Affairs  will review  the protocol,  eCRF,  regulatory 
obligations, and other material or equipment relevant to the conduct of the study  with the 
Investigator/Sub -Investigator and relevant study site personnel.  
Monitoring visits and telephone consultations will occur as necessary, or per the 
monitoring plan, during the course of the investigati on to verify the following:  
• the rights  and well-being  of subjects  are protected  
• the conduct of the investigation is in compliance with the currently approved 
protocol/amendment, 21CFR Parts 50, 54, 56 and 812, 42 USC 282(j) and with 
consideration of the provision in: ISO [ZIP_CODE] -1:2009 Clinical investigation  of medical 
devices  for human  subjects  – Part 1: General  requirements;  [ZIP_CODE] -2:2009  Part 2: 
Study  #932  - Protocol  
Date:  13FEB2019  Page  43 of 65  
 Clinical investigation of medical devices for human subjects – Part 2: Clinical 
investigational  plan;  ISO [ZIP_CODE]:2009  Ophthalmic  Optics  – Contact  [CONTACT_599857] – Guidance for clinical investigations; ICH GCPs; and applicable 
local regulations.  
• the integrity  of the data,  including  adequate  study  documentation  
• the facilities  remain  acceptable  
• the Investigator  and site personnel  remain  qualified  and able to conduct  the study  
• test article  accountability  
During the course of the study, if the Sponsor determines that an Investigator is not 
compliant with the protocol and/or applicable regulatory requirements, the Sponsor will 
take action  to secure  compliance.  In addition,  the Sponsor  may terminate  the Investigator’s 
participation   in  the  study   if  appropriate,   or  if  the  Investigator   remains 
non-compliant despi[INVESTIGATOR_240342]’s actions.  
 
9.[ADDRESS_794327]’s 
record  (source  documentation)  in real time as it is collected.  Source  documentation  consists 
of original  subject  documents,  as well as data and records  with information  relevant  to the 
subject and his/her participation in the study.  
Examples of source documents include: hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, signed ICFs, evaluation checklists, recorded data from 
automated  instruments,  copi[INVESTIGATOR_62016], and information initially recorded in an electronic format. Source documentation 
worksheets may be provided by [CONTACT_240387].  
Subject completed forms are also considered to be source data.  In no instance, should an 
Investigator  or study  site personnel  record any  data or make  changes to  subject  completed 
forms. The Investigator or designee should review subject completed forms dur ing study 
visits for completeness and accuracy. If an entry is found to be illegible or a mistake is 
found  (e.g.,  incorrect year  was recorded),  the subject  should  be instructed  to edit the entry 
by [CONTACT_740] a single line through the original entry, entering  the new information, and 
dating and initialing the change.  
 
9.[ADDRESS_794328] data required by [CONTACT_240388]. 
The Investigator and his/her study site personnel wil l be responsible for completing the 
eCRFs. The Investigator is required to verify that all of the requested information is 
accurately recorded on the eCRFs. All information required on the eCRFs needs to be 
supplied, including  subject identification and in itials, date(s), assessment values, etc., and 
any omission or discrepancy will require explanation. All information on eCRFs must be 
traceable to source documents.  
The CRA  will be responsible  for reviewing  and verifying  the data recorded  on the eCRFs, 
utilizing the original source documentation, and will query discrepant findings. The 
Investigator and study site personnel will be responsible for answering all queries.  
The eCRF data will be reviewed for completeness, accuracy, consistency, and med ical 
sense.  Programmed  edit checks  will be used to reduce  data entry  errors  and identify  unusual 
data for verification prior to statistical analysis.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  [ADDRESS_794329]’s records must be maintained to ensure adherence to applicable 
local privacy regulations.  
The investigators have to retain records for [ADDRESS_794330] is 
approved by t he FDA. The Investigator agrees to adhere to the document retention 
procedures when signing the protocol Investigator Statement of Approval.  
Essential  documents  include  but are not limited  to the following:  
• Device  Investigator  Agreement  
• IRB approvals  for the study  protocol,  all amendments,  ICF(s),  and advertisements  
• IRB annual  study  review  
• IRB correspondence  and reports  (e.g.,  AE reports,  protocol  deviations,  and safety 
updates)  
• regulatory  documents  (e.g.,  financial  disclosure  and delegation  of authority  forms)  
• all source  documents  
• eCRFs  
• subject’s  signed  ICF (including  HIPAA)  
• accountability  records  for the test article(s)  
• correspondence  from  and to the Sponsor  
• any other  documents  relevant  to the conduct  of the study  
In the event  that study records  are transferred  to another  location,  the Investigator  will 
provide notice of such transfer in writing to Bausch + Lomb Clinical Operations.  
 
9.5 Auditing  Procedures  
Audits of clinical research activities in accordance with the Sponsor’ s internal Standard 
Operating Procedures to evaluate compliance with the principles of GCP may  take place. 
A regulatory  authority  may also wish  to conduct  an inspection  (during  the study  or after its 
completion). If an inspection is requested by a regulatory authority and/or IRB, the 
Investigator must inform the Sponsor immediately that this request has been made.  
 
9.[ADDRESS_794331]  
The Investigator  should  ensure  that the following  are approved  by [CONTACT_599858],  or 
if not using  their institution's  IRB,  approved  by [CONTACT_599859]:  
• The protocol  
• The Investigator’s  participation  in the study  
• Subject  recruitment  materials  (written  information  or materials  including  web pages, 
radio  advertisements,  television  spots  or written  text developed  to encourage  subject 
enrollment)  
• The ICF to be used in this study.  
Documentation of IRB approval of the study protocol and informed consent must be 
provided  to the Sponsor  prior  to initiation  of the study.  In addition,  the Investigator  must  
Study  #932  - Protocol  
Date:  13FEB2019  Page  45 of 65  
 ensure  that the reviewing  IRB has provided  approval  for any protocol  amendments  prior  to 
implementation. If the amendment necessitates a revision to the ICF, the Investigator 
should ensure the revised form is also submitted to and approved by [CONTACT_599860].  
 
9.7 Publication  of Results  
All study data generated as a result of this study will be regarded as confidential, until 
appropriate analysis and review by  [CONTACT_239792](s) are 
completed. The results of the study may be published or presented by [CONTACT_737](s) 
after review by, and in consultation and agreement with, the Sponsor, and such that 
confidential or proprietary  information is not disclosed.  
Prior to publication or presentation, a copy of the final text should be forwarded by [CONTACT_3786](s) to the Sponsor or its designee, for comment. Such comments shall aim to 
ensure  the scientific  integrity  of the proposed  publications  and/or  presentations  and ensure 
that the  data and material referring  to Bausch + Lomb  products  and activities  receive fair, 
accurate, and reasonable presentation.  
Study  #932  - Protocol  
Date:  13FEB2019  Page  46 of 65  
 10.0 REFERENCES  
 
 
1 Bausch + Lomb Study 872 ‘A Safety and Effectiveness Study of a New Contact [CONTACT_599861]’ Final Clinical Study Report, (Version 1, 
14MAR2016)  
2 Newcombe RG (1988) Interval estimation for the difference between independent 
proport ions: comparison of eleven methods.  Statistics in Medicine 17:873 -890. 
Study  #932  - Protocol  
Date:  13FEB2019  Page  A-1  
  
 
APPENDIX  A: SCHEDULE  OF VISITS  AND  PARAMETERS  
All study tasks should be performed by [CONTACT_599862].  
 
 
 
PROCEDURES  / ASSESSMENTS   
Screening/Dispensing  2-Week 
Follow - 
up 
Visit  1- 
Month 
Follow - 
up Visit  2- 
Month 
Follow - 
up Visit  3- 
Month 
Follow - 
up Visit   
 
Exit 
Visit   
 
Unscheduled 
Visit  Post 
Study 
Follow - 
Up 
Visit  Day 0 Day 
10-18 Day 26- 
34 Day 53- 
67 Day 83- 
97 
Informed  Consent  / HIPAA  Authorization  X        
Eligibility  X        
Demographics  X        
Adverse  events,  Culture  taken   X X X X  X  
Baseline  Lens  / Lens  Care  History  X        
Lens  Wear  Parameters  X X X X X  X  
Initial  Lens  Performance  Assessment  Form 
(Worn Lenses Performance Rating Scales)  X        
Lens Performance Assessment Form 
(Study  Lenses  Performance  Rating  Scales)  X X X X X  X  
Exit Form  (if an Exit Visit  took place)  Xa X X X X X X X 
Subject  Completed  Forms  
Initial  Symptoms/Complaintsb 
(Worn  Lenses  Symptoms/Complaints  Form)  X        
Symptoms/Complaints  
(Abbreviated  Study  Lenses  Symptoms/Complaints)  X        
Symptoms/Complaints  Formb (Study  Lenses 
Symptoms/Complaints)   
X X X X  
X  
Without  Lenses  
Spherocylindrical  refraction  X     X  X 
High  contrast  distance  BSCVA  X     X  X 
Study  #932  - Protocol  
Date:  13FEB2019  Page  A-2  
  
 
 
 
 
PROCEDURES  / ASSESSMENTS   
Screening/Dispensing  2-Week 
Follow - 
up 
Visit  1- 
Month 
Follow - 
up Visit  2- 
Month 
Follow - 
up Visit  3- 
Month 
Follow - 
up Visit   
 
Exit 
Visit   
 
Unscheduled 
Visit  Post 
Study 
Follow - 
Up 
Visit  Day [ADDRESS_794332] distance BSCVA       X  X 
Compare  final keratometry  to screening  / dispensing 
keratometry       X   
With  Lenses  Worn  to Visit  
High  Contrast  Distance  lens VA  X X X X  X  
Over -refraction  and distance  VA  X X X X  X  
Lens  wettability   X X X X  X  
Lens  discoloration   X X X X  X  
Lens  deposits  (type,  percent  and degree)   X X X X  X  
Lens  centration   X X X X  X  
Lens  movement   X X X X  X  
Compare high contrast distance lens VA to high 
contrast  distance  VA at Screening  / Dispensing  Visit   X X X X  X  
With  Newly  Dispensed  Lenses  
High  Contrast  Distance  lens VA X  X X   X  
Over -refraction  and distance  VA X  X X   X  
Lens  wettability  X  X X   X  
Lens  centration  X  X X   X  
Lens  movement  X  X X   X  
Compare  high contrast  distance  lens VA to high 
contrast BSCVA  X        
Compare  high contrast  distance  lens VA to high 
contrast VA at Screening/Dispensing Visit    X X   X  
Study  #932  - Protocol  
Date:  13FEB2019  Page  A-3  
  
 
 
 
 
PROCEDURES  / ASSESSMENTS   
Screening/Dispensing  2-Week 
Follow - 
up 
Visit  1- 
Month 
Follow - 
up Visit  2- 
Month 
Follow - 
up Visit  3- 
Month 
Follow - 
up Visit   
 
Exit 
Visit   
 
Unscheduled 
Visit  Post 
Study 
Follow - 
Up 
Visit  Day 0 Day 
10-18 Day 26- 
34 Day 53- 
67 Day 83- 
97 
Study  Materials  
Dispense  Lenses  (record  lens brand,  sphere  power, 
base curve); If replacement lens, record reason for 
replacement   
X   
X  
X    
X  
Dispense  Study  kit bottles  1, 2, 3 and 4 (keep  bottle  5 
as a reserve at the site);  X        
Dispense  Study  Kit reserve  (Bottle  5, if needed)   X X X   X  
Dispense  other  supplies  as needed  (see Protocol 
Section 4.4.3)  X X X X   X  
Collect  worn  lenses  from  subject    X X X X X  
Collect  used and unused  bottles  of study  solutions      X X   
Return  study  materials  to sponsor      X X   
a At the screening  visit,  only complete  the Exit Form  if the subject  was randomized.  
b Use provided  rating  scales  (separate  document).  
Note:  All VA measurements  MUST  be made  using  a phoropter.  
Note:  If this is an Exit Visit,  also perform  the procedures  listed  under  the Exit Visit  column.  
Study  #932  - Protocol  
13FEB2019  Page  B-1  
 

Study  #932  - Protocol  
13FEB2019  Page  B-2  
 

Study  #932  - Protocol  
13FEB2019  Page  B-3  
 

Study  #932  - Protocol  
13FEB2019  Page  B-4  
 

Study  #932  - Protocol  
13FEB2019  Page  B-5  
 

Study  #932  - Protocol  
13FEB2019  Page  B-6  
 

Study  #932  - Protocol  
13FEB2019  Page  B-7  
 

Study  #932  - Protocol  
13FEB2019  Page  B-8  
 

Study  #932  - Protocol  
13FEB2019  Page  B-9  
 

Study  #932  - Protocol  
13FEB2019  Page  B-10  
 

Study  #932  - Protocol  
13FEB2019  Page  B-11  
  
 
 

Study  #932  - Protocol  
13FEB2019  Page  B-12  
 

Study  #932  - Protocol  
13FEB2019  Page  B-13  
 

Study  #[ADDRESS_794333]  INSTRUCTIONS:  
This is a “masked” clinical study in which the Investigators and Coordinators cannot see 
the Study  Solutions  or Study  Lens  Cases  that are dispensed  to you. There  will be a special 
study employee – the “unmasked designee” – at the site who will dispense all  study 
materials  to you in a white  opaque  bag and who will handle  any questions  you have  related 
to the study materials.  
 
It is very important  that you do not bring  the study  solutions  or lens cases  to the 
study site unless they are in the white opaque bag.  APPENDIX  C: SUBJECT  INSTRUCTIONS  
SUBJECT  INSTRUCTIONS  (Page  1 of 3) 
PLEASE  READ  THESE  INSTRUCTIONS  CAREFULLY  AND  KEEP  FOR  FUTURE  USE.  DO NOT  BRING 
WITH YOU TO THE FOLLOW -UP VISITS.  
You will be participating  in a study  evaluating  the clinical  performance  of two multipurpose  soft contact  [CONTACT_599863]. Please keep all appointments and follow these instructions thoroughly . If you have any questions or 
problems, call your study doctor. Remember to bring your glasses to all examinations.  
NOTE : Wear  your  study  lenses  to each  of your  follow -up visits . 
 
 
STUDY  PRODUCT  INFORMATION:  
For this study,  you will be using  the following  products:  
• Study  Contact  [CONTACT_32993].  
o You will be provided with  new pairs  of your current  contact  [CONTACT_599864],  and 
then again at the 1 -Month and 2 -Month Follow -Up Visits. 
• A Study  Kit. You will be provided  with a Study  Kit that will contain:  
o [ADDRESS_794334] an 
investigational  label  including  the Study  Kit number  (a unique  5-digit number)  and a bottle  number 
(bottles 1, 2, 3 or 4).  A fifth bottle will be retained at the site in case replenishment is required.  
o Study  Lens  case.  A study  lens case will be included  with each  carton  of study  solution  for the 
subject to use for the month.  You are required to use the study lens case.  
o Subject  Instructions.  Will be included with  each carton  of study  solution. 
• Other  Study  Supplies.  The following  supplies  will be provided  to you as needed:  
o Carton/Bottle  Return  Materials.  Comprised  of opaque  drawstring  bags and pre-printed labels 
for return of Study Solutions (full, partially filled, and empty bottles) to the Sponsor.  
o Lens  Return  Materials.  Comprised  of sealable  plastic  bags and pre-printed  labels  for return  of 
worn lenses (in a fresh lens case with the approved saline solution) to the Sponsor.  
o Sensitive  Eyes® Rewetting  Drops 
 
 
Study  #[ADDRESS_794335]  INSTRUCTIONS  (continued)  
SUBJECT  INSTRUCTIONS  (Page  2 of 3) 
GENERAL  INFORMATION:  
• Do NOT use  any products  other  than those  listed  above  or dispensed  to you  by [CONTACT_599865].  
• Do NOT  use any other  care products  other  than those  listed above.  
• Do not use any topi[INVESTIGATOR_599823]  (eye drops)  during  this study.  
• Do NOT  discuss  or show  the dispensed  study  products  or these  Subject  Instructions  to the Investigator  or 
site staff during the study.  
• Please save all study materials during the course of the study, and plan to bring all opened and unopened 
study solutions with you to th e 3-month follow -up visit.  Place the solution bottles back into the cartons. 
Place  the cartons  containing  the bottles  into the opaque  drawstring  bag provided.  Seal the bag before  going 
to the office.  
• Always  wash  and rinse  your hands  before  you handle  your lenses.  
• Always  handle  the same  lens (right  or left) first, to avoid  mix-ups. 
• Always  keep  the products  tightly  closed when  not in use. 
• Since you  are wearing  your lenses  on a daily  wear  basis, you  will be using  the Study  Solution  daily  to 
clean, rinse, disinfect and store your lenses.  
 
 
PRECAUTIONS:  
• Lens  care procedures  recommended  by [CONTACT_599866].  
• Failure  to follow  these  procedures  may result  in the development  of serious  eye infections.  
• Discard  the Study  Solution  from  the lens case after each use. 
• Store  Study  Solution  at room  temperature  
• Use Study  Solution  before  the expi[INVESTIGATOR_599824].  
• Do not use any eye medication  in conjunction  with this Study  Solution  unless  under  medical  supervision.  
• Do not touch  the bottle  tip of the Study  Solution  to any surface  or to your eye since  this may contaminate  the 
Study  solution . 
• Keep  the Study  Solution  cap closed  when  not in use to avoid  contamination  or evaporation.  
• Do not use Study  Solution  with a heat disinfection  method.  
• Keep  Study  Solution  out of reach  of children.  
• Consult  with your study  doctor  if you have  any allergies  that may affect  your ability  to use the  Study  solution . 
 
IMPORTANT:  
• If irritation  or excessive  tearing  occurs,  persists  or increases, or  if vision  is impaired,  discontinue use  and 
promptly consult your study doctor.  
Study  #[ADDRESS_794336]  INSTRUCTIONS  (continued)  
 
SUBJECT  INSTRUCTIONS  (Page  3 of 3) 
When  used as directed,  the Study  Solution : (1) Cleans,  loosens  and removes  accumulations  of film,  protein  and 
other deposits from soft contact [CONTACT_13276], and (2) Rinses and stores your soft contact [CONTACT_13276].  
 
 
GENERAL  INSTRUCTIONS:  
• Always  wash  and rinse  your hands  before  you handle  your contac t lenses.  
• Lenses  must  be thoroughly  cleaned,  rinsed,  and soaked  each time they are removed  to achieve  disinfection.  
• Rinse  each case well with the Study  Solution  before  and after each use. 
 
LENS  CLEANING  INSTRUCTIONS  (RUB  REGIMEN):  
FOR  DAILY  CLEANING/PROTEIN  REMOVAL  DISINFECTION  AND  STORING  
• Remove  the right  lens from  your right  eye. 
• Place  lens in lens case first 
• Thoroughly  rinse  each side of the lens for 5 seconds  with multi -purpose  solution  
• Place cleaned contact [CONTACT_599867] -purpose solution. Soak at least [ADDRESS_794337]  solution  from  lens case after each use. Be sure that the lens is 
completely immersed in fresh Study Solution . 
• Secure  the cap and repeat  the procedure  with the other  lens. 
 
Your  lenses  are now ready  for wear.  No rinse  is necessary.  If any debris  remains  on your lenses,  rinse  with Study 
Solution prior to insertion.  
 
 
CARE  OF THE  STUDY  LENS  STORAGE  CASE:  
• When  the study  lens case is not in use for storage  of lenses,  pour the Study  Solution  out of the lens case and 
rinse the case with fresh Study Solution . 
• Leave  the case with the caps off to dry in the air. 
• For visits  to the clinic, you  do not need  to bring  the lens case to  the clinic.  
• If there  is a reason  to bring  the lens  case to the clinic,  PLACE  THE  LENS  CASE  IN THE  WHITE  OPAQUE 
BAG FOR TRANSFER TO THE CLINIC.  
 
 
REWETTING:  
• If necessary, you  can use the supplied  rewetting  drops  while  wearing  your lenses.  Simply  place  one or two drops 
of the supplied Sensitive Eyes rewetting drops in each eye and blink 2 or 3 times.  
• If your lenses  become  dry while you  are wearing  them,  directly  apply  the Sensitive  Eyes  rewetting  drops  to 
restore moisture and maintain comfortable lens wear.  
• If lens discomfort  persists,  discontinue  use, remove  your lenses  and contact  [CONTACT_599868].  